<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE collection SYSTEM "BioC.dtd">
<collection><source>PMC</source><date>20220802</date><key>pmc.key</key><document><id>9334857</id><infon key="license">CC BY</infon><passage><infon key="article-id_doi">10.3389/fneur.2022.887164</infon><infon key="article-id_pmc">9334857</infon><infon key="article-id_pmid">35911902</infon><infon key="elocation-id">887164</infon><infon key="kwd">COVID-19 SARS-CoV-2 anosmia cerebrospinal fluid neuroinvasion</infon><infon key="license">This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</infon><infon key="name_0">surname:Purja;given-names:Sujata</infon><infon key="name_1">surname:Oh;given-names:SuA</infon><infon key="name_2">surname:Kim;given-names:EunYoung</infon><infon key="section_type">TITLE</infon><infon key="type">front</infon><infon key="volume">13</infon><infon key="year">2022</infon><offset>0</offset><text>A Systematic Review on Neurological Aspects of COVID-19: Exploring the Relationship Between COVID-19-Related Olfactory Dysfunction and Neuroinvasion</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract_title_1</infon><offset>149</offset><text>Objectives</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract</infon><offset>160</offset><text>To identify neurological aspects of Coronavirus disease 2019 (COVID-19) and to investigate COVID-19 infected patients with and without olfactory dysfunction in relation to polymerase chain reaction (PCR) assay results for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) in the cerebrospinal fluid (CSF).</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract_title_1</infon><offset>477</offset><text>Methods</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract</infon><offset>485</offset><text>PubMed and EMBASE databases were searched until March 26, 2021, for observational studies with COVID-19 patients that had performed CSF PCR assay due to the neurologic symptom and reported anosmia status.</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract_title_1</infon><offset>690</offset><text>Results</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract</infon><offset>698</offset><text>Initially, 2,387 studies were identified;167 studies performed SARS-CoV-2 CSF PCR assay, of which our review comprised 45 observational studies that conducted CSF PCR assay for SARS-CoV-2 in 101 patients and reported anosmia status in 55 of 101 patients. Central and peripheral neurological manifestations observed in COVID-19 patients were diverse. The most common neurological diagnoses were Guillain-Barré syndrome (GBS) and its variants (24%), followed by encephalopathy (21%). The SARS-CoV-2 PCR assay was positive in only four CSF samples, of which two patients had olfactory dysfunction while the others did not.</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract_title_1</infon><offset>1319</offset><text>Conclusions</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract</infon><offset>1331</offset><text>The neurological spectrum of COVID-19 is diverse, and direct neuroinvasion of SARS-CoV-2 is rare. The neuroprotection against SARS-CoV-2 in COVID-19 patients with anosmia is controversial, as an equal number of patients with and without olfactory dysfunction had positive CSF PCR results for SARS-CoV-2 in our study, and further studies are required to provide more insight into this topic.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">title_1</infon><offset>1722</offset><text>Introduction</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>1735</offset><text>The olfactory nerve connects the nasal cavity to the central nervous system (CNS) and provides a neuroinvasive shortcut to respiratory neurotropic viruses. The detection of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) in the olfactory nerve and CNS of patients with coronavirus disease 2019 (COVID-19) suggests that SARS-CoV-2 has neuroinvasive potential via the olfactory pathway. Although SARS-CoV-2 neuroinvasion is uncommon, CNS viral transmission poses a significant threat to life.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>2239</offset><text>Previous animal studies have demonstrated that respiratory neurotropic viral invasion induces apoptosis of olfactory receptor neurons (ORNs), preventing the viral transmission to the olfactory bulb and the CNS. Although the exact mechanism underlying COVID-19 related anosmia is unclear, human and animal studies have shown that anosmia is a consequence of a host defense mechanism against viral invasion involving the damage of olfactory epithelium might provide neuroprotection. Furthermore, anosmia is frequently seen in milder forms of COVID-19 with a lower mortality rate. Therefore, neuroprotection is anticipated in COVID-19 patients with anosmia.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>2894</offset><text>Understanding the underlying mechanism and prognostic value of COVID-19-related anosmia will aid better patient management since olfactory dysfunction is often associated with several neurological disorders. This systematic review aimed to compile studies involving COVID-19 patients with neurological manifestations who have undergone polymerase chain reaction (PCR) testing for SARS-CoV-2 in cerebrospinal fluid (CSF) and reported the patient's anosmia status for identifying neurological aspects of COVID-19 and exploring the COVID-19 infected patients with or without anosmia in relation to their CSF PCR assay results.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_1</infon><offset>3518</offset><text>Methods</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>3526</offset><text>Eligibility Criteria</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>3547</offset><text>The observational studies related to CSF analysis of COVID-19 patients with neurological symptoms were included. Target patients were COVID-19 patients diagnosed based on either positive SARS-CoV-2 PCR or serologic testing who had a neurological manifestation and have undergone SARS-CoV-2 CSF PCR testing to identify COVID-19-related neurological disorders. Studies that conducted CSF PCR assay for SARS-CoV-2 but did not report information on the status of anosmia were excluded. The study covered primary, retrievable scientific literature available in English. Collected data were each patient's sex and age distribution, SAR-CoV-2 CSF PCR assay, neurological presentation, treatment, and outcome. Therefore, studies that did not report these data properly were also excluded.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>4328</offset><text>Search Strategy</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>4344</offset><text>We conducted a broad literature search of databases such as EMBASE and PubMed until March 26, 2021, following preferred reporting items for systematic reviews and meta-analysis (PRISMA) checklist for studies that performed CSF PCR assay for SARS-CoV-2 in COVID-19 patients using population search terms “SARS-CoV-2” or “COVID-19” and intervention search terms “brain” or “cerebrospinal fluid” or “anosmia”.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>4771</offset><text>Study Selection</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>4787</offset><text>Two independent authors screened studies based on the titles and abstracts. Any studies relevant to the CSF analysis of patients with COVID-19 were advanced to the second stage of the review. Full texts were reviewed using the eligibility criteria mentioned above in the second screening. Any disagreement between the authors was resolved by discussion.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>5141</offset><text>Risk of Bias Assessment</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>5165</offset><text>The Joanna Briggs Institute (JBI) critical appraisal checklist was used to assess the risk of bias in each included study.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>5288</offset><text>Data Extraction and Analysis</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>5317</offset><text>Two authors independently collected the data items included in the study design for each eligible study. For evaluating neurological aspects of COVID-19, individual patient data on neurological presentation, treatment, and outcomes were collected. The data items included individual's age and sex distribution, CSF PCR assay result, anosmia status, COVID-19-related neurological symptoms, neurological diagnosis, treatment, and outcomes. Each COVID-19 patient's data with neurological manifestations who had undergone CSF PCR testing for SARS-CoV-2 to identify COVID-19-related neurological disorders was summarized to characteristics, clinical presentation, SARS-CoV-2 PCR assay results, neurological diagnosis, treatment, and outcomes.</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">title_1</infon><offset>6055</offset><text>Results</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">title_2</infon><offset>6063</offset><text>Study Selection</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>6079</offset><text>In total, 2,387 studies were identified through a literature search after removing duplicates. After preliminary screening based on the titles and abstracts, a total of 379 studies related to CSF analysis of COVID-19 patients with neurological symptoms were included; among them, 167 studies (44%) that conducted PCR tests for SARS-CoV-2 in CSF were selected for full-text review. A total of 122 studies that conducted CSF PCR assay for SARS-CoV-2 but did not report information on the status of anosmia were excluded. Thus, only 45 articles that met the inclusion criteria were included in our study. A flow diagram of the study selection process is shown in Figure 1.</text></passage><passage><infon key="file">fneur-13-887164-g0001.jpg</infon><infon key="id">F1</infon><infon key="section_type">FIG</infon><infon key="type">fig_caption</infon><offset>6749</offset><text>PRISMA flowchart.</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">title_2</infon><offset>6767</offset><text>Risk of Bias</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>6780</offset><text>Overall, the risk of bias in the included studies was low except for three studies. The summary of JBI critical appraisal results for case reports and case series can be seen in Supplementary Tables 1, 2.</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">title_2</infon><offset>6985</offset><text>Participants and Characteristics of Studies</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>7029</offset><text>The total number of participants was 104, while the SARS-CoV-2 CSF PCR testing was performed on only 101 patients. Table 1 shows the characteristics of the 101 participants included in the review. More than 63.4% (64/101) were men. The mean age was 57 ± 16.37 years. The number of men and women infected with COVID-19 increased with age. COVID-19 infected patients of both sexes, predominantly in the 60–79 age group (Figure 2).</text></passage><passage><infon key="file">T1.xml</infon><infon key="id">T1</infon><infon key="section_type">TABLE</infon><infon key="type">table_caption</infon><offset>7461</offset><text>Characteristics of studies included in the review.</text></passage><passage><infon key="file">T1.xml</infon><infon key="id">T1</infon><infon key="section_type">TABLE</infon><infon key="type">table</infon><infon key="xml">&lt;?xml version=&quot;1.0&quot; encoding=&quot;UTF-8&quot;?&gt;
&lt;table frame=&quot;hsides&quot; rules=&quot;groups&quot;&gt;&lt;thead&gt;&lt;tr&gt;&lt;th valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;
&lt;bold&gt;References&lt;/bold&gt;
&lt;/th&gt;&lt;th valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;
&lt;bold&gt;Total case&lt;/bold&gt;
&lt;/th&gt;&lt;th valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;
&lt;bold&gt;Age/sex&lt;/bold&gt;
&lt;/th&gt;&lt;th valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;
&lt;bold&gt;SARS-CoV-2 diagnostic&lt;/bold&gt;
&lt;/th&gt;&lt;th valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;
&lt;bold&gt;CSF PCR&lt;/bold&gt;
&lt;/th&gt;&lt;th valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;
&lt;bold&gt;LOS&lt;/bold&gt;
&lt;/th&gt;&lt;th valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;
&lt;bold&gt;Neurological diagnosis&lt;/bold&gt;
&lt;/th&gt;&lt;th valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;
&lt;bold&gt;Treatment&lt;/bold&gt;
&lt;/th&gt;&lt;th valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;
&lt;bold&gt;Outcome&lt;/bold&gt;
&lt;/th&gt;&lt;/tr&gt;&lt;/thead&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; colspan=&quot;9&quot; rowspan=&quot;1&quot;&gt;
&lt;bold&gt;Case report&lt;/bold&gt;
&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Andriuta et al. &lt;xref rid=&quot;B15&quot; ref-type=&quot;bibr&quot;&gt;15&lt;/xref&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;2&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;&lt;sup&gt;NR&lt;/sup&gt;/F&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NPS&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Neg&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Yes&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Encephalopathy&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NR&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NR&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;&lt;sup&gt;NR&lt;/sup&gt;/M&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NS&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Neg&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NR&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Encephalopathy&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NR&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Unawaken&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Assini et al. &lt;xref rid=&quot;B16&quot; ref-type=&quot;bibr&quot;&gt;16&lt;/xref&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;2&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;55/M&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;OPS&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Neg&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Yes&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Polyradicoloneuritis&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Idrossichlorochine, arbidol, L/R, IVIG&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Non-fatal&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;60/M&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NPS&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Neg&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NR&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Polyradicoloneuritis&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;HCQ, ART, Tocilizumab, IVIG&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Non-fatal&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Atakla et al. &lt;xref rid=&quot;B17&quot; ref-type=&quot;bibr&quot;&gt;17&lt;/xref&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;41/M&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NPS&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Neg&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Yes&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;GBS&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;IVIG, AZ, chloroquine&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Non-fatal&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Bigaut et al. &lt;xref rid=&quot;B18&quot; ref-type=&quot;bibr&quot;&gt;18&lt;/xref&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;2&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;43/M&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NPS&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Neg&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Yes&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;GBS&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;IVIG&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Non-fatal&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;70/F&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NPS&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Neg&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Yes&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;GBS&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;IVIG&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Non-fatal&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Bodro et al. &lt;xref rid=&quot;B19&quot; ref-type=&quot;bibr&quot;&gt;19&lt;/xref&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;2&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;25/M&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NPS&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Neg&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;No&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Encephalitis&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;AC, antibiotics&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Non-fatal&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;49/M&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NPS&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Neg&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;No&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Encephalitis&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;AC, antibiotics&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Non-fatal&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Canavero et al. &lt;xref rid=&quot;B20&quot; ref-type=&quot;bibr&quot;&gt;20&lt;/xref&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;2&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;25/F&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NPS&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Neg&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Yes&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Post-infectious demyelinating myelitis&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Steroid&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Non-fatal&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;69/M&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NPS&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Neg&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NR&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Encephalomyelitis&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;CF, AC, L/R, HCQ, steroid, IVIG&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Non-fatal&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Casez et al. &lt;xref rid=&quot;B21&quot; ref-type=&quot;bibr&quot;&gt;21&lt;/xref&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;96/F&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Serology&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Neg&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Yes&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Encephalitis&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NR&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NR&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Cebrián et al. &lt;xref rid=&quot;B22&quot; ref-type=&quot;bibr&quot;&gt;22&lt;/xref&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;74/F&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NPS&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Pos&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;No&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Headache&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NSAIDs, CF, HCQ, L/R&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Non-fatal&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Chakraborty et al. &lt;xref rid=&quot;B23&quot; ref-type=&quot;bibr&quot;&gt;23&lt;/xref&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;59/F&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NPS, OPS&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Neg&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;No&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Acute transverse myelitis&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Steroids and antipyretics&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Fatal&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Chan et al. &lt;xref rid=&quot;B24&quot; ref-type=&quot;bibr&quot;&gt;24&lt;/xref&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;58/M&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;OPS&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Neg&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;No&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;GBS&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;IVIG&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Non-fatal&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Chauffier et al. &lt;xref rid=&quot;B25&quot; ref-type=&quot;bibr&quot;&gt;25&lt;/xref&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;47/M&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NPS&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Neg&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;No&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Encephalopathy&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;No medical treatment&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Non-fatal&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Chaumont et al. &lt;xref rid=&quot;B26&quot; ref-type=&quot;bibr&quot;&gt;26&lt;/xref&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;69/M&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;BAL&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Neg&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Yes&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Meningoencephalitis&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;AC, HCQ, AZ&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Non-fatal&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Chow et al. &lt;xref rid=&quot;B27&quot; ref-type=&quot;bibr&quot;&gt;27&lt;/xref&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;60/M&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NPS&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Neg&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Yes&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Acute transverse myelitis&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Steroid&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Non-fatal&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Civardi et al. &lt;xref rid=&quot;B28&quot; ref-type=&quot;bibr&quot;&gt;28&lt;/xref&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;72/F&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NPS&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Neg&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Yes&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;GBS&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;IVIG, HCQ, Doxycycline&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Non-fatal&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Cohen et al. &lt;xref rid=&quot;B29&quot; ref-type=&quot;bibr&quot;&gt;29&lt;/xref&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;45/M&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NPS&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Neg&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Yes&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Parkinson's disease&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Steroid, biperiden&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Non-fatal&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Corrêa et al. &lt;xref rid=&quot;B30&quot; ref-type=&quot;bibr&quot;&gt;30&lt;/xref&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;51/F&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NS&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Neg&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Yes&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Enecephalomyeloradiculitis&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Steroid, PE, azathioprine&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Non-fatal&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;De Gennaro et al. &lt;xref rid=&quot;B31&quot; ref-type=&quot;bibr&quot;&gt;31&lt;/xref&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;2&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;42/M&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NPS&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Neg&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;No&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Cranial neuritis&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Remdesivir, sedatives, curare, IVIG&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Non-fatal&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;67/M&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NPS&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Neg&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;No&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Cranial neuritis&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Antibiotics, anesthetic, noradrenalin, IVIG&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Non-fatal&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Demirci Otluoglu et al. &lt;xref rid=&quot;B32&quot; ref-type=&quot;bibr&quot;&gt;32&lt;/xref&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;48/M&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;CSF&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Pos&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Yes&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Encephalomyelitis&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;HCQ, Favipiravir, P/T,levetiracetam, steroid, AC&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Non-fatal&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Dijkstra et al. &lt;xref rid=&quot;B33&quot; ref-type=&quot;bibr&quot;&gt;33&lt;/xref&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;44/M&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NPS&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Neg&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Yes&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Myoclonic syndrome&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Steroid and IVIG&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Non-fatal&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Fadakar et al. &lt;xref rid=&quot;B34&quot; ref-type=&quot;bibr&quot;&gt;34&lt;/xref&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;47/M&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NPS, OPS&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Pos&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;No&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Cerebellitis&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;L/R&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Non-fatal&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Grimaldi et al. &lt;xref rid=&quot;B35&quot; ref-type=&quot;bibr&quot;&gt;35&lt;/xref&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;72/M&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NPS&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Neg&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;No&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Encephalitis&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;IVIG, steroid, benzodiazepines&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Non-fatal&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Gutiérrez-Ortiz et al. &lt;xref rid=&quot;B36&quot; ref-type=&quot;bibr&quot;&gt;36&lt;/xref&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;2&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;50/M&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;OPS&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Neg&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Yes&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Miller fisher syndrome&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;IVIG&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Non-fatal&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;39/M&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;OPS&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Neg&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NR&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;PNC&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Acetaminophen&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Non-fatal&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Helbok et al. &lt;xref rid=&quot;B37&quot; ref-type=&quot;bibr&quot;&gt;37&lt;/xref&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;68/M&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Serology&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Neg&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Yes&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;GBS&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Steroid, IVIG, PE&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Non-fatal&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Huber et al. &lt;xref rid=&quot;B38&quot; ref-type=&quot;bibr&quot;&gt;38&lt;/xref&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;21/F&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Serology&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Neg&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Yes&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Myasthenia gravis&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;IVIG and pyridostigmine&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Non-fatal&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Le Guennec et al. &lt;xref rid=&quot;B39&quot; ref-type=&quot;bibr&quot;&gt;39&lt;/xref&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;69/M&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;TA&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Neg&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Yes&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Status epilepticus&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Levetiracetam and IVIG&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Non-fatal&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Lim et al. &lt;xref rid=&quot;B40&quot; ref-type=&quot;bibr&quot;&gt;40&lt;/xref&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;55/F&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NPS&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Neg&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Yes&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Psychotic disorder&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Benzodiazepine, antipsychotic&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Non-fatal&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Moore et al. &lt;xref rid=&quot;B41&quot; ref-type=&quot;bibr&quot;&gt;41&lt;/xref&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;28/M&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NPS&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Neg&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Yes&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Multiple sclerosis&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Steroid&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Non-fatal&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Muccioli et al. &lt;xref rid=&quot;B42&quot; ref-type=&quot;bibr&quot;&gt;42&lt;/xref&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;47/F&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NPS&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Neg&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Yes&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Encephalopathy&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Tocilizumab&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Non-fatal&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Naddaf et al. &lt;xref rid=&quot;B43&quot; ref-type=&quot;bibr&quot;&gt;43&lt;/xref&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;58/F&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Serology&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Neg&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;No&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;GBS&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;HCQ, zinc, steroid, PE&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Non-fatal&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Novi et al. &lt;xref rid=&quot;B44&quot; ref-type=&quot;bibr&quot;&gt;44&lt;/xref&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;64/F&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;CSF&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Pos&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Yes&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;ADEM&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Steroid with OPT, IVIG&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Non-fatal&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Oguz-Akarsu et al. &lt;xref rid=&quot;B45&quot; ref-type=&quot;bibr&quot;&gt;45&lt;/xref&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;53/F&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NPS&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Neg&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;No&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;GBS&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;PE, HCQ, AZ&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Non-fatal&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Palao et al. &lt;xref rid=&quot;B46&quot; ref-type=&quot;bibr&quot;&gt;46&lt;/xref&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;29/F&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Serology&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Neg&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Yes&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Multiple sclerosis&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Steroid with OPT&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Non-fatal&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Pascual-Goñi et al. &lt;xref rid=&quot;B47&quot; ref-type=&quot;bibr&quot;&gt;47&lt;/xref&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;2&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;60/F&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NPS&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Neg&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Yes&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Encephalopathy&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Thiamine, pyridoxine, HCQ, AZ&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Non-fatal&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;35/F&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NPS&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Neg&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NR&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Encephalopathy&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Thiamine and pyridoxine&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Non-fatal&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Riva et al. &lt;xref rid=&quot;B48&quot; ref-type=&quot;bibr&quot;&gt;48&lt;/xref&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;&lt;sup&gt;NR&lt;/sup&gt;/M&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Serology&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Neg&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Yes&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;GBS&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;IVIG&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Non-fatal&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Umapathi et al. &lt;xref rid=&quot;B49&quot; ref-type=&quot;bibr&quot;&gt;49&lt;/xref&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;2&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;59/M&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NPS&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Neg&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;No&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;ADEM&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Low molecular weight heparin, IVIG&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Non-fatal&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;73/M&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NPS&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Neg&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NR&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Encephalopathy&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Interferon-beta 1b, L/R, steroid&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Fatal&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Vandervorst et al. &lt;xref rid=&quot;B50&quot; ref-type=&quot;bibr&quot;&gt;50&lt;/xref&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;29/M&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NPS&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Neg&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Yes&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Encephalitis&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;HCQ, nebivolol, amlodipine, antipsychotic, benzodiazepines&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Non-fatal&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Zanin et al. &lt;xref rid=&quot;B51&quot; ref-type=&quot;bibr&quot;&gt;51&lt;/xref&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;54/F&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Pos; swab unclear&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Neg&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Yes&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Brain &amp;amp; spine demyelinating lesions&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;ART, HCQ, antiepileptics, steroid&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Non-fatal&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Zhou et al. &lt;xref rid=&quot;B52&quot; ref-type=&quot;bibr&quot;&gt;52&lt;/xref&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;26/M&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NS, OPS&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Neg&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;No&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;MOG-IgG-MD&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Steroid with OPT&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Non-fatal&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Zoghi et al. &lt;xref rid=&quot;B53&quot; ref-type=&quot;bibr&quot;&gt;53&lt;/xref&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;21/M&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Serology&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Neg&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;No&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Central demyelinating brain injury&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;PE, antibiotics, AC&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Non-fatal&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; colspan=&quot;9&quot; rowspan=&quot;1&quot;&gt;
&lt;bold&gt;Case series&lt;/bold&gt;
&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Cao et al. &lt;xref rid=&quot;B54&quot; ref-type=&quot;bibr&quot;&gt;54&lt;/xref&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;5&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;49/M&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NPS/TA&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Neg&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NR&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Encephalitis&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Steroid and PE&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Non-fatal&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;56/M&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NPS/TA&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Neg&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NR&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Encephalitis&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Steroid and PE&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Non-fatal&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;61/M&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NPS/TA&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Neg&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NR&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Encephalitis&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Steroid and PE&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Non-fatal&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;37/M&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NPS/TA&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Neg&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NR&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Encephalitis&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Steroid and PE&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Fatal&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;77/F&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NPS/TA&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Neg&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Yes&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Encephalitis&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Steroid and PE&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Fatal&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Delorme et al. &lt;xref rid=&quot;B55&quot; ref-type=&quot;bibr&quot;&gt;55&lt;/xref&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;4&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;72/M&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NPS&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Neg&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Yes&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Encephalopathy&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;IVIG&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Non-fatal&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;66/F&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NPS&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Neg&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NR&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Encephalopathy&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;IVIG and steroid&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Non-fatal&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;60/F&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NPS&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Neg&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NR&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Encephalopathy&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Steroid, antidepressants&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Non-fatal&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;69/M&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NPS&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Neg&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Yes&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Encephalopathy&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Levetiracetam, sedative, IVIG, steroid&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Non-fatal&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Manganotti et al. &lt;xref rid=&quot;B56&quot; ref-type=&quot;bibr&quot;&gt;56&lt;/xref&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;4&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;72/M&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NPS&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Neg&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Yes&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;GBS&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;HCQ, antivirals, steroid, tocilizumab&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Non-fatal&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;72/M&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NPS&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Neg&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Yes&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;GBS&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;HCQ, L/R, steroid&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Non-fatal&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;49/F&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NPS&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Neg&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Yes&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;GBS&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;HCQ, L/R, steroid&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Non-fatal&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;76/M&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NPS&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Neg&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Yes&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;GBS&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;HCQ, antivirals, steroid, tocilizumab, antibiotics, fluconazole&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Non-fatal&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Neumann et al. &lt;xref rid=&quot;B57&quot; ref-type=&quot;bibr&quot;&gt;57&lt;/xref&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;30&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;81/M&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NPS&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Neg&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NR&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;TIA&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NR&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NR&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;25/F&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NPS&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Neg&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NR&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;CVST&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NR&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NR&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;48/F&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;BAL&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Neg&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NR&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Encephalitis-HSV-1&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NR&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NR&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;73/F&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NPS&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Neg&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NR&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Suspected post-stroke movement disorder&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NR&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NR&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;63/M&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;BAL&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Neg&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NR&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Miller fisher syndrome&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NR&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NR&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;58/M&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;BAL&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Neg&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NR&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Encephalopathy with Seizure&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NR&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NR&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;75/F&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NPS&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Neg&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Yes&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Encephalopathy DD limbic Encephalitis&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NR&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NR&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;66/M&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NPS, BAL&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Neg&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NR&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Intracranial hemorrhage&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NR&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NR&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;56/M&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;OPS, BAL&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Neg&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NR&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Encephalopathy, CIP&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NR&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NR&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;41/F&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;OPS&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Neg&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NR&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Osmotic demyelination syndrome&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NR&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NR&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;68/M&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;BAL&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Neg&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NR&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Seizure&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NR&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NR&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;64/M&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;OPS, BAL&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Neg&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NR&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Encephalopathy, CIP&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NR&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NR&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;57/M&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;OPS, BAL&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Neg&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NR&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Status epilepticus&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NR&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NR&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;75/M&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;OPS, BAL&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Neg&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NR&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Encephalopathy, CIP&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NR&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NR&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;47/M&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;OPS, BAL&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Neg&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NR&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Encephalopathy, CIP&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NR&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NR&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;50/M&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;OPS, BAL&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Neg&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NR&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Seizure&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NR&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NR&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;51/M&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;OPS, BAL&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Neg&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NR&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Encephalopathy&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NR&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NR&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;65/F&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;OPS&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Neg&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NR&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Encephalopathy&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NR&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NR&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;45/M&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;OPS&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Neg&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NR&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Unclear headache&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NR&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NR&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;68/F&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;OPS&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Neg&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NR&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Encephalopathy&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NR&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NR&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;81/M&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;OPS, BAL&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Neg&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NR&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Encephalopathy&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NR&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NR&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;48/M&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;OPS&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Neg&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Yes&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;UVN&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NR&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NR&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;58/F&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;OPS&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Neg&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NR&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;UANP&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NR&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NR&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;80/M&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;OPS&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Neg&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Yes&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Encephalopathy&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NR&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NR&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;70/M&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;OPS, BAL&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Neg&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NR&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;CIP, Ischemic stroke&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NR&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NR&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;76/F&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;OPS, BAL&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Neg&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NR&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Prolonged coma&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NR&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NR&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;79/F&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;OPS, BAL&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Neg&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NR&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;GBS and encephalopathy&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NR&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NR&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;28/F&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;OPS&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Neg&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NR&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Ischemic stroke&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NR&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NR&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;68/M&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;OPS&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Neg&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NR&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Seizures&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NR&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NR&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;86/F&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;OPS&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Neg&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NR&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;GBS&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NR&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NR&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Perrin et al. &lt;xref rid=&quot;B58&quot; ref-type=&quot;bibr&quot;&gt;58&lt;/xref&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;5&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;71/F&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NPS&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Neg&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NR&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Encephalopathy&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Levetiracetam and steroid&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Fatal&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;64/M&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NPS&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Neg&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NR&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Encephalopathy&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;L/R, benzodiazepine, steroid, IVIG&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Non-fatal&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;53/F&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NPS&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Neg&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NR&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Encephalopathy&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;HCQ&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Non-fatal&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;51/M&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NPS&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Neg&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NR&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Encephalopathy&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;HCQ&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Non-fatal&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;67/M&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NPS&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Neg&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Yes&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Encephalopathy&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;HCQ, steroids&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Non-fatal&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Toscano et al. &lt;xref rid=&quot;B59&quot; ref-type=&quot;bibr&quot;&gt;59&lt;/xref&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;5&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;77/F&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NPS&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Neg&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NR&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;GBS&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;IVIG&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Non-fatal&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;23/M&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NPS&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Neg&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NR&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;GBS&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;IVIG&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Non-fatal&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;55/M&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NPS&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Neg&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NR&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;GBS&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;IVIG&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Non-fatal&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;76/M&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NPS&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Neg&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Yes&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;GBS&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;IVIG&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Non-fatal&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;61/M&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Serology&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Neg&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Yes&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;GBS&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;IVIG and PE&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Non-fatal&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;
</infon><offset>7512</offset><text>References	Total case	Age/sex	SARS-CoV-2 diagnostic	CSF PCR	LOS	Neurological diagnosis	Treatment	Outcome	 	Case report	 	Andriuta et al. 	2	NR/F	NPS	Neg	Yes	Encephalopathy	NR	NR	 			NR/M	NS	Neg	NR	Encephalopathy	NR	Unawaken	 	Assini et al. 	2	55/M	OPS	Neg	Yes	Polyradicoloneuritis	Idrossichlorochine, arbidol, L/R, IVIG	Non-fatal	 			60/M	NPS	Neg	NR	Polyradicoloneuritis	HCQ, ART, Tocilizumab, IVIG	Non-fatal	 	Atakla et al. 	1	41/M	NPS	Neg	Yes	GBS	IVIG, AZ, chloroquine	Non-fatal	 	Bigaut et al. 	2	43/M	NPS	Neg	Yes	GBS	IVIG	Non-fatal	 			70/F	NPS	Neg	Yes	GBS	IVIG	Non-fatal	 	Bodro et al. 	2	25/M	NPS	Neg	No	Encephalitis	AC, antibiotics	Non-fatal	 			49/M	NPS	Neg	No	Encephalitis	AC, antibiotics	Non-fatal	 	Canavero et al. 	2	25/F	NPS	Neg	Yes	Post-infectious demyelinating myelitis	Steroid	Non-fatal	 			69/M	NPS	Neg	NR	Encephalomyelitis	CF, AC, L/R, HCQ, steroid, IVIG	Non-fatal	 	Casez et al. 	1	96/F	Serology	Neg	Yes	Encephalitis	NR	NR	 	Cebrián et al. 	1	74/F	NPS	Pos	No	Headache	NSAIDs, CF, HCQ, L/R	Non-fatal	 	Chakraborty et al. 	1	59/F	NPS, OPS	Neg	No	Acute transverse myelitis	Steroids and antipyretics	Fatal	 	Chan et al. 	1	58/M	OPS	Neg	No	GBS	IVIG	Non-fatal	 	Chauffier et al. 	1	47/M	NPS	Neg	No	Encephalopathy	No medical treatment	Non-fatal	 	Chaumont et al. 	1	69/M	BAL	Neg	Yes	Meningoencephalitis	AC, HCQ, AZ	Non-fatal	 	Chow et al. 	1	60/M	NPS	Neg	Yes	Acute transverse myelitis	Steroid	Non-fatal	 	Civardi et al. 	1	72/F	NPS	Neg	Yes	GBS	IVIG, HCQ, Doxycycline	Non-fatal	 	Cohen et al. 	1	45/M	NPS	Neg	Yes	Parkinson's disease	Steroid, biperiden	Non-fatal	 	Corrêa et al. 	1	51/F	NS	Neg	Yes	Enecephalomyeloradiculitis	Steroid, PE, azathioprine	Non-fatal	 	De Gennaro et al. 	2	42/M	NPS	Neg	No	Cranial neuritis	Remdesivir, sedatives, curare, IVIG	Non-fatal	 			67/M	NPS	Neg	No	Cranial neuritis	Antibiotics, anesthetic, noradrenalin, IVIG	Non-fatal	 	Demirci Otluoglu et al. 	1	48/M	CSF	Pos	Yes	Encephalomyelitis	HCQ, Favipiravir, P/T,levetiracetam, steroid, AC	Non-fatal	 	Dijkstra et al. 	1	44/M	NPS	Neg	Yes	Myoclonic syndrome	Steroid and IVIG	Non-fatal	 	Fadakar et al. 	1	47/M	NPS, OPS	Pos	No	Cerebellitis	L/R	Non-fatal	 	Grimaldi et al. 	1	72/M	NPS	Neg	No	Encephalitis	IVIG, steroid, benzodiazepines	Non-fatal	 	Gutiérrez-Ortiz et al. 	2	50/M	OPS	Neg	Yes	Miller fisher syndrome	IVIG	Non-fatal	 			39/M	OPS	Neg	NR	PNC	Acetaminophen	Non-fatal	 	Helbok et al. 	1	68/M	Serology	Neg	Yes	GBS	Steroid, IVIG, PE	Non-fatal	 	Huber et al. 	1	21/F	Serology	Neg	Yes	Myasthenia gravis	IVIG and pyridostigmine	Non-fatal	 	Le Guennec et al. 	1	69/M	TA	Neg	Yes	Status epilepticus	Levetiracetam and IVIG	Non-fatal	 	Lim et al. 	1	55/F	NPS	Neg	Yes	Psychotic disorder	Benzodiazepine, antipsychotic	Non-fatal	 	Moore et al. 	1	28/M	NPS	Neg	Yes	Multiple sclerosis	Steroid	Non-fatal	 	Muccioli et al. 	1	47/F	NPS	Neg	Yes	Encephalopathy	Tocilizumab	Non-fatal	 	Naddaf et al. 	1	58/F	Serology	Neg	No	GBS	HCQ, zinc, steroid, PE	Non-fatal	 	Novi et al. 	1	64/F	CSF	Pos	Yes	ADEM	Steroid with OPT, IVIG	Non-fatal	 	Oguz-Akarsu et al. 	1	53/F	NPS	Neg	No	GBS	PE, HCQ, AZ	Non-fatal	 	Palao et al. 	1	29/F	Serology	Neg	Yes	Multiple sclerosis	Steroid with OPT	Non-fatal	 	Pascual-Goñi et al. 	2	60/F	NPS	Neg	Yes	Encephalopathy	Thiamine, pyridoxine, HCQ, AZ	Non-fatal	 			35/F	NPS	Neg	NR	Encephalopathy	Thiamine and pyridoxine	Non-fatal	 	Riva et al. 	1	NR/M	Serology	Neg	Yes	GBS	IVIG	Non-fatal	 	Umapathi et al. 	2	59/M	NPS	Neg	No	ADEM	Low molecular weight heparin, IVIG	Non-fatal	 			73/M	NPS	Neg	NR	Encephalopathy	Interferon-beta 1b, L/R, steroid	Fatal	 	Vandervorst et al. 	1	29/M	NPS	Neg	Yes	Encephalitis	HCQ, nebivolol, amlodipine, antipsychotic, benzodiazepines	Non-fatal	 	Zanin et al. 	1	54/F	Pos; swab unclear	Neg	Yes	Brain &amp; spine demyelinating lesions	ART, HCQ, antiepileptics, steroid	Non-fatal	 	Zhou et al. 	1	26/M	NS, OPS	Neg	No	MOG-IgG-MD	Steroid with OPT	Non-fatal	 	Zoghi et al. 	1	21/M	Serology	Neg	No	Central demyelinating brain injury	PE, antibiotics, AC	Non-fatal	 	Case series	 	Cao et al. 	5	49/M	NPS/TA	Neg	NR	Encephalitis	Steroid and PE	Non-fatal	 			56/M	NPS/TA	Neg	NR	Encephalitis	Steroid and PE	Non-fatal	 			61/M	NPS/TA	Neg	NR	Encephalitis	Steroid and PE	Non-fatal	 			37/M	NPS/TA	Neg	NR	Encephalitis	Steroid and PE	Fatal	 			77/F	NPS/TA	Neg	Yes	Encephalitis	Steroid and PE	Fatal	 	Delorme et al. 	4	72/M	NPS	Neg	Yes	Encephalopathy	IVIG	Non-fatal	 			66/F	NPS	Neg	NR	Encephalopathy	IVIG and steroid	Non-fatal	 			60/F	NPS	Neg	NR	Encephalopathy	Steroid, antidepressants	Non-fatal	 			69/M	NPS	Neg	Yes	Encephalopathy	Levetiracetam, sedative, IVIG, steroid	Non-fatal	 	Manganotti et al. 	4	72/M	NPS	Neg	Yes	GBS	HCQ, antivirals, steroid, tocilizumab	Non-fatal	 			72/M	NPS	Neg	Yes	GBS	HCQ, L/R, steroid	Non-fatal	 			49/F	NPS	Neg	Yes	GBS	HCQ, L/R, steroid	Non-fatal	 			76/M	NPS	Neg	Yes	GBS	HCQ, antivirals, steroid, tocilizumab, antibiotics, fluconazole	Non-fatal	 	Neumann et al. 	30	81/M	NPS	Neg	NR	TIA	NR	NR	 			25/F	NPS	Neg	NR	CVST	NR	NR	 			48/F	BAL	Neg	NR	Encephalitis-HSV-1	NR	NR	 			73/F	NPS	Neg	NR	Suspected post-stroke movement disorder	NR	NR	 			63/M	BAL	Neg	NR	Miller fisher syndrome	NR	NR	 			58/M	BAL	Neg	NR	Encephalopathy with Seizure	NR	NR	 			75/F	NPS	Neg	Yes	Encephalopathy DD limbic Encephalitis	NR	NR	 			66/M	NPS, BAL	Neg	NR	Intracranial hemorrhage	NR	NR	 			56/M	OPS, BAL	Neg	NR	Encephalopathy, CIP	NR	NR	 			41/F	OPS	Neg	NR	Osmotic demyelination syndrome	NR	NR	 			68/M	BAL	Neg	NR	Seizure	NR	NR	 			64/M	OPS, BAL	Neg	NR	Encephalopathy, CIP	NR	NR	 			57/M	OPS, BAL	Neg	NR	Status epilepticus	NR	NR	 			75/M	OPS, BAL	Neg	NR	Encephalopathy, CIP	NR	NR	 			47/M	OPS, BAL	Neg	NR	Encephalopathy, CIP	NR	NR	 			50/M	OPS, BAL	Neg	NR	Seizure	NR	NR	 			51/M	OPS, BAL	Neg	NR	Encephalopathy	NR	NR	 			65/F	OPS	Neg	NR	Encephalopathy	NR	NR	 			45/M	OPS	Neg	NR	Unclear headache	NR	NR	 			68/F	OPS	Neg	NR	Encephalopathy	NR	NR	 			81/M	OPS, BAL	Neg	NR	Encephalopathy	NR	NR	 			48/M	OPS	Neg	Yes	UVN	NR	NR	 			58/F	OPS	Neg	NR	UANP	NR	NR	 			80/M	OPS	Neg	Yes	Encephalopathy	NR	NR	 			70/M	OPS, BAL	Neg	NR	CIP, Ischemic stroke	NR	NR	 			76/F	OPS, BAL	Neg	NR	Prolonged coma	NR	NR	 			79/F	OPS, BAL	Neg	NR	GBS and encephalopathy	NR	NR	 			28/F	OPS	Neg	NR	Ischemic stroke	NR	NR	 			68/M	OPS	Neg	NR	Seizures	NR	NR	 			86/F	OPS	Neg	NR	GBS	NR	NR	 	Perrin et al. 	5	71/F	NPS	Neg	NR	Encephalopathy	Levetiracetam and steroid	Fatal	 			64/M	NPS	Neg	NR	Encephalopathy	L/R, benzodiazepine, steroid, IVIG	Non-fatal	 			53/F	NPS	Neg	NR	Encephalopathy	HCQ	Non-fatal	 			51/M	NPS	Neg	NR	Encephalopathy	HCQ	Non-fatal	 			67/M	NPS	Neg	Yes	Encephalopathy	HCQ, steroids	Non-fatal	 	Toscano et al. 	5	77/F	NPS	Neg	NR	GBS	IVIG	Non-fatal	 			23/M	NPS	Neg	NR	GBS	IVIG	Non-fatal	 			55/M	NPS	Neg	NR	GBS	IVIG	Non-fatal	 			76/M	NPS	Neg	Yes	GBS	IVIG	Non-fatal	 			61/M	Serology	Neg	Yes	GBS	IVIG and PE	Non-fatal	 	</text></passage><passage><infon key="file">T1.xml</infon><infon key="id">T1</infon><infon key="section_type">TABLE</infon><infon key="type">table_foot</infon><offset>14318</offset><text>AC, acyclovir; ADEM, Acute disseminating encephalomyelitis; ART, antiretroviral therapy; AZ, azithromycin; BAL, Bronchoalveolar lavage; CF, ceftriaxone; CIP, critical illness polyneuropathy; CSF, cerebrospinal fluid; CVST, Cerebral venous sinus thrombosis; DD, differential diagnosis; GBS, Guillain-Barré syndrome; HCQ, hydroxychloroquine; HSV, herpes simplex virus; IVIG, intravenous immunoglobulin; LOS, loss of smell; L/R, lopinavir and ritonavir; MOG-IgG-MD, myelin oligodendrocyte glycoprotein- antibody-mediated disease; NPS, nasopharyngeal swab; NS, nasal swab; NSAIDs, Non-steroidal anti-inflammatory drug; OPS, oropharyngeal swab; OPT, oral prednisolone tapering; PCR, polymerase chain reaction; PE, plasma exchange; PNC, Polyneuritis cranialis; P/T, piperacillin and tazobactam; SARS-CoV-2, severe acute respiratory syndrome coronavirus-2; TA, tracheal aspirate; TIA, Transient ischemic attack; UVN, Unilateral Vestibular Neuritis.</text></passage><passage><infon key="file">T1.xml</infon><infon key="id">T1</infon><infon key="section_type">TABLE</infon><infon key="type">table_foot</infon><offset>15261</offset><text>NR denotes data not reported in the studies, F means female, M means male, Pos means positive, and Neg means negative.</text></passage><passage><infon key="file">fneur-13-887164-g0002.jpg</infon><infon key="id">F2</infon><infon key="section_type">FIG</infon><infon key="type">fig_caption</infon><offset>15380</offset><text>Age and sex distribution of COVID-19 patients who underwent CSF PCR assay for SARS-CoV-2. The number of men and women infected with COVID-19 who developed severe neurological manifestations and underwent CSF PCR assay for SARS-CoV-2 increased as the age of the individuals increased. The impact of COVID-19 was higher in patients aged 60-70 years old of both sexes. In addition, there were more COVID-19 infected men than COVID-19 infected women of all ages. COVID-19, coronavirus disease 2019; CSF, cerebrospinal fluid; PCR, polymerase chain reaction; SARS-CoV-2, severe acute respiratory syndrome coronavirus-2. NR denotes that the ages of two males and one female were not reported.</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">title_2</infon><offset>16066</offset><text>Neurological Aspects of COVID-19</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">title_3</infon><offset>16099</offset><text>Clinical Presentation</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>16121</offset><text>The neurological symptoms observed in COVID-19 individuals were diverse. The most common COVID-19-related neurological symptoms were smell disorder, taste disorder, headache, myalgia, altered consciousness, related paresis, and related cognitive and behavioral disturbances.</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">title_3</infon><offset>16396</offset><text>Neurological Diagnosis</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>16419</offset><text>The neurological diagnosis made after the neurological and radiological examination was localized to CNS (61.39%), peripheral nervous system (32.67%), or both (5.94%). In a study comprising 30 participants, six patients were diagnosed with two neurological disorders. The most common neurological diagnosis included Guillain-Barré syndrome and its variant (24%), followed by encephalopathy (21%) (Table 1).</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">title_3</infon><offset>16827</offset><text>Treatment and Outcomes</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>16850</offset><text>Information on the therapeutic management of COVID-19 was available for only 69 patients, including one patient who did not require medical treatment. In most cases, therapeutic management of COVID-19 patients involved combinational therapies. Common treatments included steroids administration (n = 32/69), intravenous immunoglobulin infusion (n = 28/69), hydroxychloroquine (n = 18/69), and plasma exchange (n = 11/69). Other medications used in the management of COVID-19 patients are shown in Table 1. The administration of medications resulted in neurological improvement in most patients. There were 63 non-fatal cases, five fatal cases, and one patient did not regain consciousness even after sedation was discontinued.</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">title_3</infon><offset>17577</offset><text>SARS-CoV-2 PCR Assay Results</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>17606</offset><text>Patients were confirmed to be COVID-19 positive when tested positive in PCR assay from nasopharyngeal swab or nasal swab (50/101), oropharyngeal swab (14/101), bronchoalveolar lavage (5/101), tracheal aspirate (1/101), or a combination of them (20/101). The PCR assay was positive in one study, but the swab used was not specified. Two patients were confirmed COVID-19 positive with the presence of SARS-CoV-2 in CSF, and in eight patients with negative PCR test, COVID-19 infection was diagnosed with the presence of anti-SARS-CoV-2 in serum (Table 1).</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>18160</offset><text>CSF PCR assay for SARS-CoV-2 was positive for only four (3.96%) patients and negative in 97 (96.04%) patients. Of the 101 patients, information on the status of anosmia was available in 55 patients (51 patients had negative CSF PCR results, while four had positive CSF PCR results). Out of 51 patients with negative CSF PCR results, 38 had smell disorder, while 13 had no nasal symptoms. Meanwhile, two of the four patients with positive CSF PCR results for SARS-CoV-2 had olfactory dysfunction, while the other two did not (Table 1).</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">title_1</infon><offset>18695</offset><text>Discussion</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>18706</offset><text>This systematic review identified studies that performed CSF PCR assay for SARS-CoV-2 in COVID-19 positive patients and reported anosmia status to identify the common neurological manifestations associated with COVID-19 and to analyze the interrelation between CSF PCR results and anosmia. The neurological manifestations of COVID-19 are diverse. There was an equal number of patients with and without olfactory disorders who had positive CSF PCR results for SARS-CoV-2.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>19177</offset><text>COVID-19 can trigger other autoimmune neurological complications such as neuromyelitis optica spectrum disorders or multiple sclerosis, which should be identified and treated promptly. In addition, COVID-19 patients with olfactory disorders and other severe neurological symptoms should be examined for possible neurodegenerative disease when suspected of having one.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>19545</offset><text>In our study, ~4% of the participants had positive CSF PCR assay for SARS-CoV-2, similar to the finding of one study, which showed positive results in 6% of the participants, indicating SARS-CoV-2 neuroinvasion is a rare occurrence. However, negative CSF PCR results for SARS-CoV-2 may be due to delayed immune-mediated neurological damage after viral clearance. Furthermore, the sensitivity decreases if samples are tested after a long period of symptom onset, giving negative results. In addition, according to our review, only 44% of the published articles on CSF studies performed CSF PCR assay for SARS-CoV-2 in COVID-19 infected patients who experienced neurological symptoms. Therefore, despite the procedural and logistical complexity, the authors suggest an early collection of CSF samples, performing CSF PCR assay for SARS-CoV-2, detecting anti-neuronal autoantibodies, and using 18 F-fluorodeoxyglucose positron emission tomography in suspected cases could aid in the diagnosis and management of the patients, notably in magnetic resonance imaging negative cases. Although the additional financial concern associated with the CSF PCR assay cannot be avoided, there were cases of testing positive in CSF PCR assay despite being negative in a nasal PCR or rapid COVID-19 test. In addition, cost-effective studies in other neurotropic viruses have shown that the CSF PCR assay is cost-effective; similar studies in COVID-19 are required. Furthermore, a negative CSF PCR assay does not rule out the presence of the virus in the CNS; therefore, further studies of SARS-CoV-2 antibodies are required. Moreover, a recent study has shown that SARS-CoV-2 retrograde neuroinvasion via the olfactory route causes neuroinflammation. The detection of SARS-CoV-2 in the olfactory epithelium and various radiological findings in patients with COVID-19 suggests that despite the rarity of SARS-CoV-2 neuroinvasion via the olfactory system, it should not be overlooked.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>21510</offset><text>Similar to other respiratory neurotropic viruses, the direct neuroinvasion of SARS-CoV-2 in COVID-19 patients could occur mainly in two ways: damage to the olfactory epithelium or diffusion through the olfactory ensheathing cell (OEC) (Figure 3). Although ORNs of humans do not express SARS-CoV-2 entry proteins, factors other than angiotensin-converting enzyme-2 may be involved in a viral entry, such as neurolipin-1, which is highly expressed in ORNs or SARS-CoV-2 can have non-neuronal mechanism. The neuronal and non-neuronal damage of the olfactory epithelium are responsible for the mechanism of loss of smell observed in COVID-19 patients. Nevertheless, viruses that are rapidly transported to the olfactory bulb before being affected by ORN apoptotic actions may invade the CNS.</text></passage><passage><infon key="file">fneur-13-887164-g0003.jpg</infon><infon key="id">F3</infon><infon key="section_type">FIG</infon><infon key="type">fig_caption</infon><offset>22298</offset><text>Possible mechanisms of neuroinvasion of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) via the olfactory pathway. SARS-CoV-2 can enter the central nervous system (CNS) through the olfactory system in one of two ways: directly through the cerebrospinal fluid (CSF) by crossing the channels created by olfactory ensheathing cells (OECs) (purple straight line) or through olfactory receptor neurons (ORNs). Since ORNs lack angiotensin-converting enzyme-2 (ACE-2), viruses are hypothesized to be transferred from sustentacular (SUS) cells, which contain ACE-2, either directly to mature ORNs (mORNs) or to stem cells (also containing ACE-2), which can then transfer the virus to immature ORNs (iORNs) during ORN regeneration process, where infected iORNs could grow into infected mORNs. The pink dotted line represents the hypotheses. Viruses can directly enter the CNS from ORN through ACE-2-independent mechanisms (green straight line) using factors such as neurolipin-1. The blue straight line represents the regeneration of ORNs and SUS cells from stem cells.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>23372</offset><text>In addition, viruses as small as 100nm can also diffuse via the channels formed by OEC gaining direct access to the CSF. The size of SARS-CoV-2 ranges from 60 to 140 nm. Additionally, direct infection of the OEC can release viruses into these channels and subsequently transport the virus to the olfactory bulb. Thus, SARS-CoV-2 with a smaller size can utilize this mode of viral transmission.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>23766</offset><text>Studies analyzing the olfactory mucosa of COVID-19 patients with and without anosmia are required to acknowledge that apoptosis of ORNs is the cause of COVID-19-related anosmia. Future studies with a larger sample size involving nasal brush sampling method and CSF PCR assay can be performed on COVID-19 patients to determine whether apoptosis of ORNs could provide neuroprotection in COVID-19 patients with anosmia.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>24183</offset><text>This study has several limitations. Olfactory mucosa biopsy is required to effectively analyze the association between apoptosis of ORNs with anosmia and neuroprotection. However, few studies were included in this analysis. Because the biopsy is an invasive procedure, it is rarely done in patients with COVID-19 only for research purposes, unlike animal studies. Additionally, studies that determine whether apoptosis of ORNs occurs in COVID-19 patients experiencing anosmia and SARS-CoV-2 CSF PCR assays are not available. For these reasons, the study design for analyzing the hypothesis was only feasible with observational studies. Though the risk of bias assessment showed an overall low risk, fundamental bias from the study design cannot be fully excluded. The findings from this review are not directly comparable with the results from other neurotropic viruses till these unanswered issues are solved. The number of patients with positive CSF PCR results did not differ by anosmia status, which may be related to the limited sample size and non-standard CSF PCR assay procedures. The CSF PCR assay is not commonly performed in COVID-19 patients with neurological manifestation. In this study, among COVID-19 patients with neurological manifestation, only 44% of patients underwent PCR assay for SARS-CoV-2 in the CSF to identify COVID-19 related neurological disorders. Though anosmia is common in COVID-19 patients, underreporting issues cannot be ignored, and because of limitation to our methodology, the neurological manifestations observed in individuals with COVID-19 cannot be generalized. Similarly, the possibility of an indirect mechanism of neuroinvasion of SARS-CoV-2 should not be overlooked. We could not investigate the neurological aspects of different strains of SARS-CoV-2 in COVID-19 infected patients and geographical and temporal relationships, particularly those concerning olfactory alteration, because information about the SARS-CoV-2 strain along with geographical and temporal information was not available in the included studies. Future studies with proper sample sizes involving definitive methods such as the nasal mucosa sampling method could provide a clear answer to the association between apoptosis of ORNs with anosmia and neuroprotection.</text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">title_1</infon><offset>26468</offset><text>Conclusion</text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">paragraph</infon><offset>26479</offset><text>The neurological spectrum of COVID-19 is wide. Direct neuroinvasion of SARS-CoV-2 via the olfactory route is uncommon. Although previous experimental models of respiratory neurotropic viruses have demonstrated that apoptosis of the olfactory nerve blocks its neuroinvasive ability, this remains controversial in the case of SARS-CoV-2, since at present, human evidence is too scare limiting any conclusion to be drawn about the protection role of virus' olfactory mucosa invasion toward CNS invasion. More research with definitive methods is required to study the neuroprotective potential of ORN apoptosis in COVID-19 patients.</text></passage><passage><infon key="section_type">SUPPL</infon><infon key="type">title_1</infon><offset>27108</offset><text>Data Availability Statement</text></passage><passage><infon key="section_type">SUPPL</infon><infon key="type">paragraph</infon><offset>27136</offset><text>The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding author/s.</text></passage><passage><infon key="section_type">AUTH_CONT</infon><infon key="type">title_1</infon><offset>27303</offset><text>Author Contributions</text></passage><passage><infon key="section_type">AUTH_CONT</infon><infon key="type">paragraph</infon><offset>27324</offset><text>EK had full access to all the data in the study and took responsibility for the integrity of the data and the accuracy of the data analysis. SP and EK: conceptualization, writing original draft, and formal analysis. SP, SO, and EK: data acquisition and writing review and editing. EK: funding and supervision. All authors contributed to the article and approved the submitted version.</text></passage><passage><infon key="section_type">ACK_FUND</infon><infon key="type">title_1</infon><offset>27709</offset><text>Funding</text></passage><passage><infon key="section_type">ACK_FUND</infon><infon key="type">paragraph</infon><offset>27717</offset><text>This work was funded by a grant from the Korean government, South Korea (Ministry of Science and ICT, MICT; NRF-2021R1F1A1062044) and by the Basic Science Research Program through the National Research Foundation of Korea funded by the Ministry of Education, South Korea (Grant Number 2021R1A6A1A03044296). The funder had no role in the trial design, data collection, data interpretation, or report preparation.</text></passage><passage><infon key="section_type">COMP_INT</infon><infon key="type">title_1</infon><offset>28129</offset><text>Conflict of Interest</text></passage><passage><infon key="section_type">COMP_INT</infon><infon key="type">paragraph</infon><offset>28150</offset><text>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</text></passage><passage><infon key="section_type">COMP_INT</infon><infon key="type">title_1</infon><offset>28323</offset><text>Publisher's Note</text></passage><passage><infon key="section_type">COMP_INT</infon><infon key="type">paragraph</infon><offset>28340</offset><text>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</text></passage><passage><infon key="section_type">SUPPL</infon><infon key="type">title_1</infon><offset>28687</offset><text>Supplementary Material</text></passage><passage><infon key="section_type">SUPPL</infon><infon key="type">paragraph</infon><offset>28710</offset><text>The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fneur.2022.887164/full#supplementary-material</text></passage><passage><infon key="section_type">REF</infon><infon key="type">title</infon><offset>28869</offset><text>References</text></passage><passage><infon key="fpage">277</infon><infon key="lpage">87</infon><infon key="name_0">surname:Van Riel;given-names:D</infon><infon key="name_1">surname:Verdijk;given-names:R</infon><infon key="name_2">surname:Kuiken;given-names:T</infon><infon key="pub-id_doi">10.1002/path.4461</infon><infon key="pub-id_pmid">25294743</infon><infon key="section_type">REF</infon><infon key="source">J Pathol.</infon><infon key="type">ref</infon><infon key="volume">235</infon><infon key="year">2015</infon><offset>28880</offset><text>The olfactory nerve: a shortcut for influenza other viral diseases into the central nervous system</text></passage><passage><infon key="fpage">168</infon><infon key="lpage">175</infon><infon key="name_0">surname:Meinhardt;given-names:J</infon><infon key="name_1">surname:Radke;given-names:J</infon><infon key="name_2">surname:Dittmayer;given-names:C</infon><infon key="name_3">surname:Franz;given-names:J</infon><infon key="name_4">surname:Thomas;given-names:C</infon><infon key="name_5">surname:Mothes;given-names:R</infon><infon key="pub-id_doi">10.1101/2020.06.04.135012</infon><infon key="pub-id_pmid">33257876</infon><infon key="section_type">REF</infon><infon key="source">Nat. Neurosci</infon><infon key="type">ref</infon><infon key="volume">24</infon><infon key="year">2021</infon><offset>28979</offset><text>Olfactory transmucosal SARS-CoV-2 invasion as a port of central nervous system entry in individuals with COVID-19</text></passage><passage><infon key="fpage">117316</infon><infon key="name_0">surname:Lewis;given-names:A</infon><infon key="name_1">surname:Frontera;given-names:J</infon><infon key="name_2">surname:Placantonakis;given-names:DG</infon><infon key="name_3">surname:Lighter;given-names:J</infon><infon key="name_4">surname:Galetta;given-names:S</infon><infon key="name_5">surname:Balcer;given-names:L</infon><infon key="pub-id_doi">10.1016/j.jns.2021.117316</infon><infon key="pub-id_pmid">33561753</infon><infon key="section_type">REF</infon><infon key="source">J Neurol Sci.</infon><infon key="type">ref</infon><infon key="volume">421</infon><infon key="year">2021</infon><offset>29093</offset><text>Cerebrospinal fluid in COVID-19: a systematic review of the literature</text></passage><passage><infon key="fpage">2109</infon><infon key="lpage">2116</infon><infon key="name_0">surname:Mori;given-names:I</infon><infon key="name_1">surname:Goshima;given-names:F</infon><infon key="name_2">surname:Imai;given-names:Y</infon><infon key="name_3">surname:Kohsaka;given-names:S</infon><infon key="name_4">surname:Sugiyama;given-names:T</infon><infon key="name_5">surname:Yoshida;given-names:T</infon><infon key="pub-id_doi">10.1099/0022-1317-83-9-2109</infon><infon key="pub-id_pmid">12185263</infon><infon key="section_type">REF</infon><infon key="source">J Gen Virol.</infon><infon key="type">ref</infon><infon key="volume">83</infon><infon key="year">2002</infon><offset>29164</offset><text>Olfactory receptor neurons prevent dissemination of neurovirulent influenza A virus into the brain by undergoing virus-induced apoptosis</text></passage><passage><infon key="fpage">209</infon><infon key="lpage">16</infon><infon key="name_0">surname:Mori;given-names:I</infon><infon key="name_1">surname:Nishiyama;given-names:Y</infon><infon key="name_2">surname:Yokochi;given-names:T</infon><infon key="name_3">surname:Kimura;given-names:Y</infon><infon key="pub-id_doi">10.1002/rmv.426</infon><infon key="pub-id_pmid">15248249</infon><infon key="section_type">REF</infon><infon key="source">Rev Med Virol.</infon><infon key="type">ref</infon><infon key="volume">14</infon><infon key="year">2004</infon><offset>29301</offset><text>Virus-induced neuronal apoptosis as pathological and protective responses of the host</text></passage><passage><infon key="fpage">1073858420956905</infon><infon key="name_0">surname:Butowt;given-names:R</infon><infon key="pub-id_doi">10.1177/1073858420956905</infon><infon key="pub-id_pmid">32914699</infon><infon key="section_type">REF</infon><infon key="source">Neuroscientist.</infon><infon key="type">ref</infon><infon key="volume">2020</infon><infon key="year">2020</infon><offset>29387</offset><text>and von Bartheld CS, Anosmia in COVID-19: underlying mechanisms and assessment of an olfactory route to brain infection</text></passage><passage><infon key="fpage">579</infon><infon key="lpage">86</infon><infon key="name_0">surname:Bryche;given-names:B</infon><infon key="name_1">surname:St Albin;given-names:A</infon><infon key="name_2">surname:Murri;given-names:S</infon><infon key="name_3">surname:Lacôte;given-names:S</infon><infon key="name_4">surname:Pulido;given-names:C</infon><infon key="name_5">surname:Ar Gouilh;given-names:M</infon><infon key="pub-id_doi">10.1016/j.bbi.2020.06.032</infon><infon key="pub-id_pmid">32629042</infon><infon key="section_type">REF</infon><infon key="source">Brain Behav Immun.</infon><infon key="type">ref</infon><infon key="volume">89</infon><infon key="year">2020</infon><offset>29507</offset><text>Massive transient damage of the olfactory epithelium associated with infection of sustentacular cells by SARS-CoV-2 in golden Syrian hamsters</text></passage><passage><infon key="fpage">109881</infon><infon key="name_0">surname:Le Bon;given-names:SD</infon><infon key="name_1">surname:Horoi;given-names:M</infon><infon key="pub-id_doi">10.1016/j.mehy.2020.109881</infon><infon key="pub-id_pmid">32474381</infon><infon key="section_type">REF</infon><infon key="source">Med Hypotheses.</infon><infon key="type">ref</infon><infon key="volume">143</infon><infon key="year">2020</infon><offset>29649</offset><text>Is anosmia the price to pay in an immune-induced scorched-earth policy against COVID-19?</text></passage><passage><infon key="fpage">eabf8396</infon><infon key="name_0">surname:de Melo;given-names:GD</infon><infon key="name_1">surname:Lazarini;given-names:F</infon><infon key="name_2">surname:Levallois;given-names:S</infon><infon key="name_3">surname:Hautefort;given-names:C</infon><infon key="name_4">surname:Michel;given-names:V</infon><infon key="name_5">surname:Larrous;given-names:F</infon><infon key="pub-id_doi">10.1126/scitranslmed.abf8396</infon><infon key="pub-id_pmid">33941622</infon><infon key="section_type">REF</infon><infon key="source">Sci Transl Med.</infon><infon key="type">ref</infon><infon key="volume">13</infon><infon key="year">2021</infon><offset>29738</offset><text>COVID-19-related anosmia is associated with viral persistence and inflammation in human olfactory epithelium and brain infection in hamsters</text></passage><passage><infon key="fpage">117163</infon><infon key="name_0">surname:Talavera;given-names:B</infon><infon key="name_1">surname:García-Azorín;given-names:D</infon><infon key="name_2">surname:Martínez-Pías;given-names:E</infon><infon key="name_3">surname:Trigo;given-names:J</infon><infon key="name_4">surname:Hernández-Pérez;given-names:I</infon><infon key="name_5">surname:Valle-Peñacoba;given-names:G</infon><infon key="pub-id_doi">10.1016/j.jns.2020.117163</infon><infon key="pub-id_pmid">33035870</infon><infon key="section_type">REF</infon><infon key="source">J Neurol Sci.</infon><infon key="type">ref</infon><infon key="volume">419</infon><infon key="year">2020</infon><offset>29879</offset><text>Anosmia is associated with lower in-hospital mortality in COVID-19</text></passage><passage><infon key="fpage">725</infon><infon key="lpage">40</infon><infon key="name_0">surname:Purja;given-names:S</infon><infon key="name_1">surname:Shin;given-names:H</infon><infon key="name_2">surname:Lee;given-names:JY</infon><infon key="name_3">surname:Kim;given-names:E</infon><infon key="pub-id_doi">10.1007/s12272-021-01344-4</infon><infon key="pub-id_pmid">34302637</infon><infon key="section_type">REF</infon><infon key="source">Arch Pharm Res.</infon><infon key="type">ref</infon><infon key="volume">44</infon><infon key="year">2021</infon><offset>29946</offset><text>Is loss of smell an early predictor of COVID-19 severity: a systematic review and meta-analysis</text></passage><passage><infon key="fpage">543275</infon><infon key="name_0">surname:Ciurleo;given-names:R</infon><infon key="name_1">surname:De Salvo;given-names:S</infon><infon key="name_2">surname:Bonanno;given-names:L</infon><infon key="name_3">surname:Marino;given-names:S</infon><infon key="name_4">surname:Bramanti;given-names:P</infon><infon key="name_5">surname:Caminiti;given-names:F</infon><infon key="pub-id_doi">10.3389/fneur.2020.543275</infon><infon key="pub-id_pmid">33240192</infon><infon key="section_type">REF</infon><infon key="source">Front Neurol.</infon><infon key="type">ref</infon><infon key="volume">11</infon><infon key="year">2020</infon><offset>30042</offset><text>Parosmia and neurological disorders: a neglected association</text></passage><passage><infon key="fpage">n71</infon><infon key="name_0">surname:Page;given-names:MJ</infon><infon key="name_1">surname:McKenzie;given-names:JE</infon><infon key="name_2">surname:Bossuyt;given-names:PM</infon><infon key="name_3">surname:Boutron;given-names:I</infon><infon key="name_4">surname:Hoffmann;given-names:TC</infon><infon key="name_5">surname:Mulrow;given-names:CD</infon><infon key="pub-id_doi">10.1136/bmj.n71</infon><infon key="pub-id_pmid">33782057</infon><infon key="section_type">REF</infon><infon key="source">BMJ.</infon><infon key="type">ref</infon><infon key="volume">372</infon><infon key="year">2021</infon><offset>30103</offset><text>The PRISMA 2020 statement: an updated guideline for reporting systematic reviews</text></passage><passage><infon key="name_0">surname:Moola;given-names:S</infon><infon key="name_1">surname:Munn;given-names:Z</infon><infon key="name_2">surname:Tufanaru;given-names:C</infon><infon key="name_3">surname:Aromataris;given-names:E</infon><infon key="name_4">surname:Sears;given-names:K</infon><infon key="name_5">surname:Sfetcu;given-names:R</infon><infon key="section_type">REF</infon><infon key="source">JBI Manual for Evidence Synthesis JBI</infon><infon key="type">ref</infon><infon key="year">2020</infon><offset>30184</offset><text>Chapter 7: systematic reviews of etiology and risk. in</text></passage><passage><infon key="fpage">2810</infon><infon key="lpage">1</infon><infon key="name_0">surname:Andriuta;given-names:D</infon><infon key="name_1">surname:Roger;given-names:PA</infon><infon key="name_2">surname:Thibault;given-names:W</infon><infon key="name_3">surname:Toublanc;given-names:B</infon><infon key="name_4">surname:Sauzay;given-names:C</infon><infon key="name_5">surname:Castelain;given-names:S</infon><infon key="pub-id_doi">10.1007/s00415-020-09975-1</infon><infon key="pub-id_pmid">32529577</infon><infon key="section_type">REF</infon><infon key="source">J Neurol.</infon><infon key="type">ref</infon><infon key="volume">267</infon><infon key="year">2020</infon><offset>30239</offset><text>COVID-19 encephalopathy: detection of antibodies against SARS-CoV-2 in CSF</text></passage><passage><infon key="fpage">1657</infon><infon key="lpage">8</infon><infon key="name_0">surname:Assini;given-names:A</infon><infon key="name_1">surname:Benedetti;given-names:L</infon><infon key="name_2">surname:Di Maio;given-names:S</infon><infon key="name_3">surname:Schirinzi;given-names:E</infon><infon key="name_4">surname:Del Sette;given-names:M</infon><infon key="pub-id_doi">10.1007/s10072-020-04484-5</infon><infon key="pub-id_pmid">32468450</infon><infon key="section_type">REF</infon><infon key="source">Neurol Sci.</infon><infon key="type">ref</infon><infon key="volume">41</infon><infon key="year">2020</infon><offset>30314</offset><text>New clinical manifestation of COVID-19 related Guillain-Barrè syndrome highly responsive to intravenous immunoglobulins: two Italian cases</text></passage><passage><infon key="fpage">150</infon><infon key="name_0">surname:Atakla;given-names:HG</infon><infon key="name_1">surname:Noudohounsi;given-names:M</infon><infon key="name_2">surname:Sacca;given-names:H</infon><infon key="name_3">surname:Tassiou;given-names:NRA</infon><infon key="name_4">surname:Noudohounsi;given-names:WC</infon><infon key="name_5">surname:Houinato;given-names:DS</infon><infon key="pub-id_doi">10.11604/pamj.supp.2020.35.2.25745</infon><infon key="pub-id_pmid">33193965</infon><infon key="section_type">REF</infon><infon key="source">Pan Afr Med J.</infon><infon key="type">ref</infon><infon key="volume">35</infon><infon key="year">2020</infon><offset>30454</offset><text>Acute Guillain-Barré polyradiculoneuritis indicative of COVID-19 infection: a case report</text></passage><passage><infon key="fpage">e785</infon><infon key="name_0">surname:Bigaut;given-names:K</infon><infon key="name_1">surname:Mallaret;given-names:M</infon><infon key="name_2">surname:Baloglu;given-names:S</infon><infon key="name_3">surname:Nemoz;given-names:B</infon><infon key="name_4">surname:Morand;given-names:P</infon><infon key="name_5">surname:Baicry;given-names:F</infon><infon key="pub-id_doi">10.1212/NXI.0000000000000785</infon><infon key="pub-id_pmid">32461235</infon><infon key="section_type">REF</infon><infon key="source">Neurol Neuroimmunol Neuroinflamm.</infon><infon key="type">ref</infon><infon key="volume">7</infon><infon key="year">2020</infon><offset>30545</offset><text>Guillain-Barré syndrome related to SARS-CoV-2 infection</text></passage><passage><infon key="fpage">e821</infon><infon key="name_0">surname:Bodro;given-names:M</infon><infon key="name_1">surname:Compta;given-names:Y</infon><infon key="name_2">surname:Llansó;given-names:L</infon><infon key="name_3">surname:Esteller;given-names:D</infon><infon key="name_4">surname:Doncel-Moriano;given-names:A</infon><infon key="name_5">surname:Mesa;given-names:A</infon><infon key="pub-id_doi">10.1212/NXI.0000000000000821</infon><infon key="pub-id_pmid">32611761</infon><infon key="section_type">REF</infon><infon key="source">Neurol Neuroimmunol Neuroinflamm.</infon><infon key="type">ref</infon><infon key="volume">7</infon><infon key="year">2020</infon><offset>30602</offset><text>Increased CSF levels of IL-1β, IL-6, and ACE in SARS-CoV-2-associated encephalitis</text></passage><passage><infon key="fpage">102000</infon><infon key="name_0">surname:Canavero;given-names:I</infon><infon key="name_1">surname:Valentino;given-names:F</infon><infon key="name_2">surname:Colombo;given-names:E</infon><infon key="name_3">surname:Franciotta;given-names:D</infon><infon key="name_4">surname:Ferrandi;given-names:D</infon><infon key="name_5">surname:Mussa;given-names:M</infon><infon key="pub-id_doi">10.1016/j.tmaid.2021.102000</infon><infon key="pub-id_pmid">33640477</infon><infon key="section_type">REF</infon><infon key="source">Travel Med Infect Dis.</infon><infon key="type">ref</infon><infon key="volume">40</infon><infon key="year">2021</infon><offset>30688</offset><text>Acute myelopathies associated to SARS-CoV-2 infection: viral or immune-mediated damage?</text></passage><passage><infon key="fpage">e645</infon><infon key="lpage">6</infon><infon key="name_0">surname:Casez;given-names:O</infon><infon key="name_1">surname:Willaume;given-names:G</infon><infon key="name_2">surname:Grand;given-names:S</infon><infon key="name_3">surname:Nemoz;given-names:B</infon><infon key="name_4">surname:Lupo;given-names:J</infon><infon key="name_5">surname:Kahane;given-names:P</infon><infon key="pub-id_doi">10.1212/WNL.0000000000011150</infon><infon key="pub-id_pmid">33154083</infon><infon key="section_type">REF</infon><infon key="source">MRI Pattern Olfact Tract Involvement Neurol.</infon><infon key="type">ref</infon><infon key="volume">96</infon><infon key="year">2021</infon><offset>30776</offset><text>Teaching neuroimages: SARS-CoV-2–related encephalitis</text></passage><passage><infon key="fpage">266</infon><infon key="lpage">8</infon><infon key="name_0">surname:Cebrián;given-names:J</infon><infon key="name_1">surname:Gonzalez-Martinez;given-names:A</infon><infon key="name_2">surname:García-Blanco;given-names:MJ</infon><infon key="name_3">surname:Celdrán-Vivancos;given-names:D</infon><infon key="name_4">surname:Palacios;given-names:EL</infon><infon key="name_5">surname:Reig-Roselló;given-names:G</infon><infon key="pub-id_doi">10.1212/WNL.0000000000010213</infon><infon key="pub-id_pmid">32641532</infon><infon key="section_type">REF</infon><infon key="source">Neurology.</infon><infon key="type">ref</infon><infon key="volume">95</infon><infon key="year">2020</infon><offset>30832</offset><text>Headache and impaired consciousness level associated with SARS-CoV-2 in CSF: a case report</text></passage><passage><infon key="fpage">e238668</infon><infon key="name_0">surname:Chakraborty;given-names:U</infon><infon key="name_1">surname:Chandra;given-names:A</infon><infon key="name_2">surname:Ray;given-names:AK</infon><infon key="name_3">surname:Biswas;given-names:P</infon><infon key="pub-id_doi">10.1136/bcr-2020-238668</infon><infon key="pub-id_pmid">32843475</infon><infon key="section_type">REF</infon><infon key="source">BMJ Case Rep.</infon><infon key="type">ref</infon><infon key="volume">13</infon><infon key="year">2020</infon><offset>30923</offset><text>COVID-19-associated acute transverse myelitis: a rare entity</text></passage><passage><infon key="fpage">852</infon><infon key="lpage">4</infon><infon key="name_0">surname:Chan;given-names:JL</infon><infon key="name_1">surname:Ebadi;given-names:H</infon><infon key="name_2">surname:Sarna;given-names:JR</infon><infon key="pub-id_doi">10.1017/cjn.2020.106</infon><infon key="pub-id_pmid">32468972</infon><infon key="section_type">REF</infon><infon key="source">Can J Neurol Sci.</infon><infon key="type">ref</infon><infon key="volume">47</infon><infon key="year">2020</infon><offset>30984</offset><text>Guillain-Barré Syndrome with facial diplegia related to SARS-CoV-2 infection</text></passage><passage><infon key="fpage">99</infon><infon key="lpage">101</infon><infon key="name_0">surname:Chauffier;given-names:J</infon><infon key="name_1">surname:Poey;given-names:N</infon><infon key="name_2">surname:Husain;given-names:M</infon><infon key="name_3">surname:de Broucker;given-names:T</infon><infon key="name_4">surname:Khalil;given-names:A</infon><infon key="name_5">surname:Lariven;given-names:S</infon><infon key="pub-id_doi">10.1016/j.medmal.2020.09.018</infon><infon key="pub-id_pmid">33027622</infon><infon key="section_type">REF</infon><infon key="source">Infect Dis Now.</infon><infon key="type">ref</infon><infon key="volume">51</infon><infon key="year">2021</infon><offset>31062</offset><text>First case of mild encephalopathy with reversible splenial lesion in SARS-CoV-2 infection</text></passage><passage><infon key="fpage">519</infon><infon key="lpage">21</infon><infon key="name_0">surname:Chaumont;given-names:H</infon><infon key="name_1">surname:Etienne;given-names:P</infon><infon key="name_2">surname:Roze;given-names:E</infon><infon key="name_3">surname:Couratier;given-names:C</infon><infon key="name_4">surname:Roger;given-names:PM</infon><infon key="name_5">surname:Lannuzel;given-names:A</infon><infon key="pub-id_doi">10.1016/j.neurol.2020.04.014</infon><infon key="pub-id_pmid">32414534</infon><infon key="section_type">REF</infon><infon key="source">Rev Neurol.</infon><infon key="type">ref</infon><infon key="volume">176</infon><infon key="year">2020</infon><offset>31152</offset><text>Acute meningoencephalitis in a patient with COVID-19</text></passage><passage><infon key="fpage">e236720</infon><infon key="name_0">surname:Chow;given-names:CCN</infon><infon key="name_1">surname:Magnussen;given-names:J</infon><infon key="name_2">surname:Ip;given-names:J</infon><infon key="name_3">surname:Su;given-names:Y</infon><infon key="pub-id_doi">10.1136/bcr-2020-236720</infon><infon key="pub-id_pmid">32784242</infon><infon key="section_type">REF</infon><infon key="source">BMJ Case Rep.</infon><infon key="type">ref</infon><infon key="volume">13</infon><infon key="year">2020</infon><offset>31205</offset><text>Acute transverse myelitis in COVID-19 infection</text></passage><passage><infon key="fpage">1361</infon><infon key="lpage">2</infon><infon key="name_0">surname:Civardi;given-names:C</infon><infon key="name_1">surname:Collini;given-names:A</infon><infon key="name_2">surname:Geda;given-names:DJ</infon><infon key="name_3">surname:Geda;given-names:C</infon><infon key="pub-id_doi">10.1136/jnnp-2020-324279</infon><infon key="pub-id_pmid">32859744</infon><infon key="section_type">REF</infon><infon key="source">J Neurol Neurosurg Psychiatry.</infon><infon key="type">ref</infon><infon key="volume">91</infon><infon key="year">2020</infon><offset>31253</offset><text>Antiganglioside antibodies in Guillain-Barré syndrome associated with SARS-CoV-2 infection</text></passage><passage><infon key="fpage">804</infon><infon key="lpage">5</infon><infon key="name_0">surname:Cohen;given-names:ME</infon><infon key="name_1">surname:Eichel;given-names:R</infon><infon key="name_2">surname:Steiner-Birmanns;given-names:B</infon><infon key="name_3">surname:Janah;given-names:A</infon><infon key="name_4">surname:Ioshpa;given-names:M</infon><infon key="name_5">surname:Bar-Shalom;given-names:R</infon><infon key="pub-id_doi">10.1016/S1474-4422(20)30305-7</infon><infon key="pub-id_pmid">32949534</infon><infon key="section_type">REF</infon><infon key="source">Lancet Neurol.</infon><infon key="type">ref</infon><infon key="volume">19</infon><infon key="year">2020</infon><offset>31345</offset><text>A case of probable Parkinson's disease after SARS-CoV-2 infection</text></passage><passage><infon key="fpage">973</infon><infon key="lpage">6</infon><infon key="name_0">surname:Corrêa;given-names:DG</infon><infon key="name_1">surname:de Souza Lima;given-names:FC</infon><infon key="name_2">surname:da Cruz Bezerra;given-names:D</infon><infon key="name_3">surname:Coutinho;given-names:AC</infon><infon key="name_4">surname:Hygino;given-names:da</infon><infon key="pub-id_doi">10.1177/1352458520949988</infon><infon key="pub-id_pmid">32909895</infon><infon key="section_type">REF</infon><infon key="source">Mult Scler.</infon><infon key="type">ref</infon><infon key="volume">27</infon><infon key="year">2021</infon><offset>31411</offset><text>Cruz LC. COVID-19 associated with encephalomyeloradiculitis and positive anti-aquaporin-4 antibodies: cause or coincidence?</text></passage><passage><infon key="fpage">1</infon><infon key="lpage">6</infon><infon key="name_0">surname:De Gennaro;given-names:R</infon><infon key="name_1">surname:Gastaldo;given-names:E</infon><infon key="name_2">surname:Tamborino;given-names:C</infon><infon key="name_3">surname:Baraldo;given-names:M</infon><infon key="name_4">surname:Casula;given-names:N</infon><infon key="name_5">surname:Pedrali;given-names:M</infon><infon key="pub-id_doi">10.1007/s10072-021-05087-4</infon><infon key="pub-id_pmid">33515336</infon><infon key="section_type">REF</infon><infon key="source">Neurol Sci</infon><infon key="type">ref</infon><infon key="volume">2021</infon><infon key="year">2021</infon><offset>31535</offset><text>Selective cranial multineuritis in severe COVID-19 pneumonia: two cases and literature review</text></passage><passage><infon key="fpage">1</infon><infon key="lpage">3</infon><infon key="name_0">surname:Demirci Otluoglu;given-names:G</infon><infon key="name_1">surname:Yener;given-names:U</infon><infon key="name_2">surname:Demir;given-names:MK</infon><infon key="name_3">surname:Yilmaz;given-names:B</infon><infon key="pub-id_doi">10.1080/02688697.2020.1787342</infon><infon key="pub-id_pmid">32633581</infon><infon key="section_type">REF</infon><infon key="source">Br J Neurosurg.</infon><infon key="type">ref</infon><infon key="volume">2020</infon><infon key="year">2020</infon><offset>31629</offset><text>Encephalomyelitis associated with Covid-19 infection: case report</text></passage><passage><infon key="fpage">974</infon><infon key="lpage">6</infon><infon key="name_0">surname:Dijkstra;given-names:F</infon><infon key="name_1">surname:Van den Bossche;given-names:T</infon><infon key="name_2">surname:Willekens;given-names:B</infon><infon key="name_3">surname:Cras;given-names:P</infon><infon key="name_4">surname:Crosiers;given-names:D</infon><infon key="pub-id_doi">10.1002/mdc3.13049</infon><infon key="pub-id_pmid">32837962</infon><infon key="section_type">REF</infon><infon key="source">(COVID-19) Mov Disord Clin Pract.</infon><infon key="type">ref</infon><infon key="volume">7</infon><infon key="year">2020</infon><offset>31695</offset><text>Myoclonus and cerebellar ataxia following Coronavirus Disease (2019)</text></passage><passage><infon key="fpage">911</infon><infon key="lpage">4</infon><infon key="name_0">surname:Fadakar;given-names:N</infon><infon key="name_1">surname:Ghaemmaghami;given-names:S</infon><infon key="name_2">surname:Masoompour;given-names:SM</infon><infon key="name_3">surname:Shirazi Yeganeh;given-names:B</infon><infon key="name_4">surname:Akbari;given-names:A</infon><infon key="name_5">surname:Hooshmandi;given-names:S</infon><infon key="pub-id_doi">10.1007/s12311-020-01177-9</infon><infon key="pub-id_pmid">32737799</infon><infon key="section_type">REF</infon><infon key="source">Cerebellum.</infon><infon key="type">ref</infon><infon key="volume">19</infon><infon key="year">2020</infon><offset>31764</offset><text>A first case of acute cerebellitis associated with coronavirus disease (COVID-19): a case report and literature review</text></passage><passage><infon key="fpage">1726</infon><infon key="lpage">9</infon><infon key="name_0">surname:Grimaldi;given-names:S</infon><infon key="name_1">surname:Lagarde;given-names:S</infon><infon key="name_2">surname:Harlé;given-names:JR</infon><infon key="name_3">surname:Boucraut;given-names:J</infon><infon key="name_4">surname:Guedj;given-names:E</infon><infon key="pub-id_doi">10.2967/jnumed.120.249292</infon><infon key="pub-id_pmid">32709734</infon><infon key="section_type">REF</infon><infon key="source">J Nucl Med.</infon><infon key="type">ref</infon><infon key="volume">61</infon><infon key="year">2020</infon><offset>31883</offset><text>Autoimmune Encephalitis Concomitant with SARS-CoV-2 infection: insight from (18)F-FDG PET imaging and neuronal autoantibodies</text></passage><passage><infon key="fpage">e601</infon><infon key="lpage">5</infon><infon key="name_0">surname:Gutiérrez-Ortiz;given-names:C</infon><infon key="name_1">surname:Méndez-Guerrero;given-names:A</infon><infon key="name_2">surname:Rodrigo-Rey;given-names:S</infon><infon key="name_3">surname:San Pedro-Murillo;given-names:E</infon><infon key="name_4">surname:Bermejo-Guerrero;given-names:L</infon><infon key="name_5">surname:Gordo-Mañas;given-names:R</infon><infon key="pub-id_doi">10.1212/WNL.0000000000009619</infon><infon key="pub-id_pmid">32303650</infon><infon key="section_type">REF</infon><infon key="source">Neurology.</infon><infon key="type">ref</infon><infon key="volume">95</infon><infon key="year">2020</infon><offset>32009</offset><text>Miller fisher syndrome and polyneuritis cranialis in COVID-19</text></passage><passage><infon key="fpage">1754</infon><infon key="lpage">6</infon><infon key="name_0">surname:Helbok;given-names:R</infon><infon key="name_1">surname:Beer;given-names:R</infon><infon key="name_2">surname:Löscher;given-names:W</infon><infon key="name_3">surname:Boesch;given-names:S</infon><infon key="name_4">surname:Reindl;given-names:M</infon><infon key="name_5">surname:Hornung;given-names:R</infon><infon key="pub-id_doi">10.1111/ene.14388</infon><infon key="pub-id_pmid">32531083</infon><infon key="section_type">REF</infon><infon key="source">Eur J Neurol.</infon><infon key="type">ref</infon><infon key="volume">27</infon><infon key="year">2020</infon><offset>32071</offset><text>Guillain-Barré syndrome in a patient with antibodies against SARS-CoV-2</text></passage><passage><infon key="fpage">576153</infon><infon key="name_0">surname:Huber;given-names:M</infon><infon key="name_1">surname:Rogozinski;given-names:S</infon><infon key="name_2">surname:Puppe;given-names:W</infon><infon key="name_3">surname:Framme;given-names:C</infon><infon key="name_4">surname:Höglinger;given-names:G</infon><infon key="name_5">surname:Hufendiek;given-names:K</infon><infon key="pub-id_doi">10.3389/fneur.2020.576153</infon><infon key="pub-id_pmid">33123081</infon><infon key="section_type">REF</infon><infon key="source">Front Neurol.</infon><infon key="type">ref</infon><infon key="volume">11</infon><infon key="year">2020</infon><offset>32144</offset><text>Postinfectious onset of myasthenia gravis in a COVID-19 patient</text></passage><passage><infon key="fpage">e90</infon><infon key="lpage">4</infon><infon key="name_0">surname:Le Guennec;given-names:L</infon><infon key="name_1">surname:Devianne;given-names:J</infon><infon key="name_2">surname:Jalin;given-names:L</infon><infon key="name_3">surname:Cao;given-names:A</infon><infon key="name_4">surname:Galanaud;given-names:D</infon><infon key="name_5">surname:Navarro;given-names:V</infon><infon key="pub-id_doi">10.1111/epi.16612</infon><infon key="pub-id_pmid">32589794</infon><infon key="section_type">REF</infon><infon key="source">Epilepsia.</infon><infon key="type">ref</infon><infon key="volume">61</infon><infon key="year">2020</infon><offset>32208</offset><text>Orbitofrontal involvement in a neuroCOVID-19 patient</text></passage><passage><infon key="fpage">e105</infon><infon key="name_0">surname:Lim;given-names:ST</infon><infon key="name_1">surname:Janaway;given-names:B</infon><infon key="name_2">surname:Costello;given-names:H</infon><infon key="name_3">surname:Trip;given-names:A</infon><infon key="name_4">surname:Price;given-names:G</infon><infon key="pub-id_doi">10.1192/bjo.2020.76</infon><infon key="pub-id_pmid">32696735</infon><infon key="section_type">REF</infon><infon key="source">BJPsych Open.</infon><infon key="type">ref</infon><infon key="volume">6</infon><infon key="year">2020</infon><offset>32261</offset><text>Persistent psychotic symptoms following COVID-19 infection</text></passage><passage><infon key="fpage">100299</infon><infon key="name_0">surname:Moore;given-names:L</infon><infon key="name_1">surname:Ghannam;given-names:M</infon><infon key="name_2">surname:Manousakis;given-names:G</infon><infon key="pub-id_doi">10.1016/j.ensci.2020.100299</infon><infon key="pub-id_pmid">33313429</infon><infon key="section_type">REF</infon><infon key="source">eNeurologicalSci.</infon><infon key="type">ref</infon><infon key="volume">22</infon><infon key="year">2021</infon><offset>32320</offset><text>first presentation of multiple sclerosis with concurrent COVID-19 infection</text></passage><passage><infon key="fpage">577400</infon><infon key="name_0">surname:Muccioli;given-names:L</infon><infon key="name_1">surname:Pensato;given-names:U</infon><infon key="name_2">surname:Cani;given-names:I</infon><infon key="name_3">surname:Guerra;given-names:L</infon><infon key="name_4">surname:Provini;given-names:F</infon><infon key="name_5">surname:Bordin;given-names:G</infon><infon key="pub-id_doi">10.1016/j.jneuroim.2020.577400</infon><infon key="pub-id_pmid">33032013</infon><infon key="section_type">REF</infon><infon key="source">J Neuroimmunol.</infon><infon key="type">ref</infon><infon key="volume">349</infon><infon key="year">2020</infon><offset>32396</offset><text>COVID-19-related encephalopathy presenting with aphasia resolving following tocilizumab treatment</text></passage><passage><infon key="fpage">1799</infon><infon key="lpage">801</infon><infon key="name_0">surname:Naddaf;given-names:E</infon><infon key="name_1">surname:Laughlin;given-names:RS</infon><infon key="name_2">surname:Klein;given-names:CJ</infon><infon key="name_3">surname:Toledano;given-names:M</infon><infon key="name_4">surname:Theel;given-names:ES</infon><infon key="name_5">surname:Binnicker;given-names:MJ</infon><infon key="pub-id_doi">10.1016/j.mayocp.2020.05.029</infon><infon key="pub-id_pmid">32753154</infon><infon key="section_type">REF</infon><infon key="source">Mayo Clin Proc.</infon><infon key="type">ref</infon><infon key="volume">95</infon><infon key="year">2020</infon><offset>32494</offset><text>Guillain-barré syndrome in a patient with evidence of Recent SARS-CoV-2 Infection</text></passage><passage><infon key="fpage">e797</infon><infon key="name_0">surname:Novi;given-names:G</infon><infon key="name_1">surname:Rossi;given-names:T</infon><infon key="name_2">surname:Pedemonte;given-names:E</infon><infon key="name_3">surname:Saitta;given-names:L</infon><infon key="name_4">surname:Rolla;given-names:C</infon><infon key="name_5">surname:Roccatagliata;given-names:L</infon><infon key="pub-id_doi">10.1212/NXI.0000000000000797</infon><infon key="pub-id_pmid">32482781</infon><infon key="section_type">REF</infon><infon key="source">Neurol Neuroimmunol Neuroinflamm.</infon><infon key="type">ref</infon><infon key="volume">7</infon><infon key="year">2020</infon><offset>32577</offset><text>Acute disseminated encephalomyelitis after SARS-CoV-2 infection</text></passage><passage><infon key="fpage">e54</infon><infon key="lpage">7</infon><infon key="name_0">surname:Oguz-Akarsu;given-names:E</infon><infon key="name_1">surname:Ozpar;given-names:R</infon><infon key="name_2">surname:Mirzayev;given-names:H</infon><infon key="name_3">surname:Acet-Ozturk;given-names:NA</infon><infon key="name_4">surname:Hakyemez;given-names:B</infon><infon key="name_5">surname:Ediger;given-names:D</infon><infon key="pub-id_doi">10.1002/mus.26992</infon><infon key="pub-id_pmid">32497292</infon><infon key="section_type">REF</infon><infon key="source">Muscle Nerve.</infon><infon key="type">ref</infon><infon key="volume">62</infon><infon key="year">2020</infon><offset>32641</offset><text>Guillain-Barré syndrome in a patient with minimal symptoms of COVID-19 infection</text></passage><passage><infon key="fpage">102377</infon><infon key="name_0">surname:Palao;given-names:M</infon><infon key="name_1">surname:Fernández-Díaz;given-names:E</infon><infon key="name_2">surname:Gracia-Gil;given-names:J</infon><infon key="name_3">surname:Romero-Sánchez;given-names:CM</infon><infon key="name_4">surname:Díaz-Maroto;given-names:I</infon><infon key="name_5">surname:Segura;given-names:T</infon><infon key="pub-id_doi">10.1016/j.msard.2020.102377</infon><infon key="pub-id_pmid">32698095</infon><infon key="section_type">REF</infon><infon key="source">Mult Scler Relat Disord.</infon><infon key="type">ref</infon><infon key="volume">45</infon><infon key="year">2020</infon><offset>32723</offset><text>Multiple sclerosis following SARS-CoV-2 infection</text></passage><passage><infon key="fpage">e823</infon><infon key="name_0">surname:Pascual-Goñi;given-names:E</infon><infon key="name_1">surname:Fortea;given-names:J</infon><infon key="name_2">surname:Martínez-Domeño;given-names:A</infon><infon key="name_3">surname:Rabella;given-names:N</infon><infon key="name_4">surname:Tecame;given-names:M</infon><infon key="name_5">surname:Gómez-Oliva;given-names:C</infon><infon key="pub-id_doi">10.1212/NXI.0000000000000823</infon><infon key="pub-id_pmid">32587102</infon><infon key="section_type">REF</infon><infon key="source">Neurol Neuroimmunol Neuroinflamm.</infon><infon key="type">ref</infon><infon key="volume">7</infon><infon key="year">2020</infon><offset>32773</offset><text>COVID-19-associated ophthalmoparesis and hypothalamic involvement</text></passage><passage><infon key="fpage">2492</infon><infon key="lpage">4</infon><infon key="name_0">surname:Riva;given-names:N</infon><infon key="name_1">surname:Russo;given-names:T</infon><infon key="name_2">surname:Falzone;given-names:YM</infon><infon key="name_3">surname:Strollo;given-names:M</infon><infon key="name_4">surname:Amadio;given-names:S</infon><infon key="name_5">surname:Del Carro;given-names:U</infon><infon key="pub-id_doi">10.1007/s00415-020-09907-z</infon><infon key="pub-id_pmid">32458192</infon><infon key="section_type">REF</infon><infon key="source">J Neurol.</infon><infon key="type">ref</infon><infon key="volume">267</infon><infon key="year">2020</infon><offset>32839</offset><text>Post-infectious Guillain-Barré syndrome related to SARS-CoV-2 infection: a case report</text></passage><passage><infon key="fpage">100275</infon><infon key="name_0">surname:Umapathi;given-names:T</infon><infon key="name_1">surname:Quek;given-names:WMJ</infon><infon key="name_2">surname:Yen;given-names:JM</infon><infon key="name_3">surname:Khin;given-names:HSW</infon><infon key="name_4">surname:Mah;given-names:YY</infon><infon key="name_5">surname:Chan;given-names:CYJ</infon><infon key="pub-id_doi">10.1016/j.ensci.2020.100275</infon><infon key="pub-id_pmid">32984561</infon><infon key="section_type">REF</infon><infon key="source">eNeurologicalSci.</infon><infon key="type">ref</infon><infon key="volume">21</infon><infon key="year">2020</infon><offset>32927</offset><text>Encephalopathy in COVID-19 patients; viral, parainfectious, or both?</text></passage><passage><infon key="fpage">100821</infon><infon key="name_0">surname:Vandervorst;given-names:F</infon><infon key="name_1">surname:Guldolf;given-names:K</infon><infon key="name_2">surname:Peeters;given-names:I</infon><infon key="name_3">surname:Vanderhasselt;given-names:T</infon><infon key="name_4">surname:Michiels;given-names:K</infon><infon key="name_5">surname:Berends;given-names:KJ</infon><infon key="pub-id_doi">10.1016/j.inat.2020.100821</infon><infon key="pub-id_pmid">32835017</infon><infon key="section_type">REF</infon><infon key="source">Interdiscip Neurosurg.</infon><infon key="type">ref</infon><infon key="volume">22</infon><infon key="year">2020</infon><offset>32996</offset><text>Encephalitis associated with the SARS-CoV-2 virus: a case report</text></passage><passage><infon key="fpage">1491</infon><infon key="lpage">4</infon><infon key="name_0">surname:Zanin;given-names:L</infon><infon key="name_1">surname:Saraceno;given-names:G</infon><infon key="name_2">surname:Panciani;given-names:PP</infon><infon key="name_3">surname:Renisi;given-names:G</infon><infon key="name_4">surname:Signorini;given-names:L</infon><infon key="name_5">surname:Migliorati;given-names:K</infon><infon key="pub-id_doi">10.1007/s00701-020-04374-x</infon><infon key="pub-id_pmid">32367205</infon><infon key="section_type">REF</infon><infon key="source">Acta Neurochir (Wien).</infon><infon key="type">ref</infon><infon key="volume">162</infon><infon key="year">2020</infon><offset>33061</offset><text>SARS-CoV-2 can induce brain and spine demyelinating lesions</text></passage><passage><infon key="fpage">398</infon><infon key="lpage">402</infon><infon key="name_0">surname:Zhou;given-names:S</infon><infon key="name_1">surname:Jones-Lopez;given-names:EC</infon><infon key="name_2">surname:Soneji;given-names:DJ</infon><infon key="name_3">surname:Azevedo;given-names:CJ</infon><infon key="name_4">surname:Patel;given-names:VR</infon><infon key="pub-id_doi">10.1097/WNO.0000000000001049</infon><infon key="pub-id_pmid">32604245</infon><infon key="section_type">REF</infon><infon key="source">J Neuroophthalmol.</infon><infon key="type">ref</infon><infon key="volume">40</infon><infon key="year">2020</infon><offset>33121</offset><text>Myelin oligodendrocyte glycoprotein antibody-associated optic neuritis and myelitis in COVID-19</text></passage><passage><infon key="fpage">102324</infon><infon key="name_0">surname:Zoghi;given-names:A</infon><infon key="name_1">surname:Ramezani;given-names:M</infon><infon key="name_2">surname:Roozbeh;given-names:M</infon><infon key="name_3">surname:Darazam;given-names:IA</infon><infon key="name_4">surname:Sahraian;given-names:MA</infon><infon key="pub-id_doi">10.1016/j.msard.2020.102324</infon><infon key="pub-id_pmid">32615528</infon><infon key="section_type">REF</infon><infon key="source">Mult Scler Relat Disord.</infon><infon key="type">ref</infon><infon key="volume">44</infon><infon key="year">2020</infon><offset>33217</offset><text>case of possible atypical demyelinating event of the central nervous system following COVID-19</text></passage><passage><infon key="fpage">e102</infon><infon key="lpage">e102</infon><infon key="name_0">surname:Cao;given-names:A</infon><infon key="name_1">surname:Rohaut;given-names:B</infon><infon key="name_2">surname:Le Guennec;given-names:L</infon><infon key="name_3">surname:Saheb;given-names:S</infon><infon key="name_4">surname:Marois;given-names:C</infon><infon key="name_5">surname:Altmayer;given-names:V</infon><infon key="pub-id_doi">10.1093/brain/awaa337</infon><infon key="pub-id_pmid">33064794</infon><infon key="section_type">REF</infon><infon key="source">Brain.</infon><infon key="type">ref</infon><infon key="volume">143</infon><infon key="year">2020</infon><offset>33312</offset><text>Severe COVID-19-related encephalitis can respond to immunotherapy</text></passage><passage><infon key="fpage">2651</infon><infon key="lpage">7</infon><infon key="name_0">surname:Delorme;given-names:C</infon><infon key="name_1">surname:Paccoud;given-names:O</infon><infon key="name_2">surname:Kas;given-names:A</infon><infon key="name_3">surname:Hesters;given-names:A</infon><infon key="name_4">surname:Bombois;given-names:S</infon><infon key="name_5">surname:Shambrook;given-names:P</infon><infon key="pub-id_doi">10.1111/ene.14478</infon><infon key="pub-id_pmid">32881133</infon><infon key="section_type">REF</infon><infon key="source">Eur J Neurol.</infon><infon key="type">ref</infon><infon key="volume">27</infon><infon key="year">2020</infon><offset>33378</offset><text>COVID-19-related encephalopathy: a case series with brain FDG-positron-emission tomography/computed tomography findings</text></passage><passage><infon key="fpage">766</infon><infon key="lpage">74</infon><infon key="name_0">surname:Manganotti;given-names:P</infon><infon key="name_1">surname:Bellavita;given-names:G</infon><infon key="name_2">surname:D'Acunto;given-names:L</infon><infon key="name_3">surname:Tommasini;given-names:V</infon><infon key="name_4">surname:Fabris;given-names:M</infon><infon key="name_5">surname:Sartori;given-names:A</infon><infon key="pub-id_doi">10.1002/jmv.26289</infon><infon key="pub-id_pmid">32662899</infon><infon key="section_type">REF</infon><infon key="source">J Med Virol.</infon><infon key="type">ref</infon><infon key="volume">93</infon><infon key="year">2021</infon><offset>33498</offset><text>Clinical neurophysiology and cerebrospinal liquor analysis to detect Guillain-Barré syndrome and polyneuritis cranialis in COVID-19 patients: a case series</text></passage><passage><infon key="fpage">117090</infon><infon key="name_0">surname:Neumann;given-names:B</infon><infon key="name_1">surname:Schmidbauer;given-names:ML</infon><infon key="name_2">surname:Dimitriadis;given-names:K</infon><infon key="name_3">surname:Otto;given-names:S</infon><infon key="name_4">surname:Knier;given-names:B</infon><infon key="name_5">surname:Niesen;given-names:WD</infon><infon key="pub-id_doi">10.1016/j.jns.2020.117090</infon><infon key="pub-id_pmid">32805440</infon><infon key="section_type">REF</infon><infon key="source">J Neurol Sci.</infon><infon key="type">ref</infon><infon key="volume">418</infon><infon key="year">2020</infon><offset>33655</offset><text>Cerebrospinal fluid findings in COVID-19 patients with neurological symptoms</text></passage><passage><infon key="fpage">248</infon><infon key="lpage">58</infon><infon key="name_0">surname:Perrin;given-names:P</infon><infon key="name_1">surname:Collongues;given-names:N</infon><infon key="name_2">surname:Baloglu;given-names:S</infon><infon key="name_3">surname:Bedo;given-names:D</infon><infon key="name_4">surname:Bassand;given-names:X</infon><infon key="name_5">surname:Lavaux;given-names:T</infon><infon key="pub-id_doi">10.1111/ene.14491</infon><infon key="pub-id_pmid">32853434</infon><infon key="section_type">REF</infon><infon key="source">Eur J Neurol.</infon><infon key="type">ref</infon><infon key="volume">28</infon><infon key="year">2021</infon><offset>33732</offset><text>Cytokine release syndrome-associated encephalopathy in patients with COVID-19</text></passage><passage><infon key="fpage">2574</infon><infon key="lpage">6</infon><infon key="name_0">surname:Toscano;given-names:G</infon><infon key="name_1">surname:Palmerini;given-names:F</infon><infon key="name_2">surname:Ravaglia;given-names:S</infon><infon key="name_3">surname:Ruiz;given-names:L</infon><infon key="name_4">surname:Invernizzi;given-names:P</infon><infon key="name_5">surname:Cuzzoni;given-names:MG</infon><infon key="pub-id_doi">10.1056/NEJMc2009191</infon><infon key="pub-id_pmid">32302082</infon><infon key="section_type">REF</infon><infon key="source">N Engl J Med.</infon><infon key="type">ref</infon><infon key="volume">382</infon><infon key="year">2020</infon><offset>33810</offset><text>Guillain-Barré syndrome associated with SARS-CoV-2</text></passage><passage><infon key="fpage">1566</infon><infon key="lpage">75</infon><infon key="name_0">surname:Hauser;given-names:RG</infon><infon key="name_1">surname:Campbell;given-names:SM</infon><infon key="name_2">surname:Brandt;given-names:CA</infon><infon key="name_3">surname:Wang;given-names:S</infon><infon key="pub-id_doi">10.1128/JCM.00119-17</infon><infon key="pub-id_pmid">28298450</infon><infon key="section_type">REF</infon><infon key="source">J Clin Microbiol.</infon><infon key="type">ref</infon><infon key="volume">55</infon><infon key="year">2017</infon><offset>33862</offset><text>Cost-effectiveness study of criteria for screening cerebrospinal fluid to determine the need for herpes simplex virus PCR testing</text></passage><passage><infon key="fpage">592</infon><infon key="lpage">5</infon><infon key="name_0">surname:Guedj;given-names:E</infon><infon key="name_1">surname:Million;given-names:M</infon><infon key="name_2">surname:Dudouet;given-names:P</infon><infon key="name_3">surname:Tissot-Dupont;given-names:H</infon><infon key="name_4">surname:Bregeon;given-names:F</infon><infon key="name_5">surname:Cammilleri;given-names:S</infon><infon key="pub-id_doi">10.1007/s00259-020-04973-x</infon><infon key="pub-id_pmid">32728799</infon><infon key="section_type">REF</infon><infon key="source">Eur J Nucl Med Mol Imaging.</infon><infon key="type">ref</infon><infon key="volume">48</infon><infon key="year">2021</infon><offset>33992</offset><text>(18)F-FDG brain PET hypometabolism in post-SARS-CoV-2 infection: substrate for persistent/delayed disorders?</text></passage><passage><infon key="fpage">861</infon><infon key="lpage">5</infon><infon key="name_0">surname:Daly;given-names:JL</infon><infon key="name_1">surname:Simonetti;given-names:B</infon><infon key="name_2">surname:Klein;given-names:K</infon><infon key="name_3">surname:Chen;given-names:KE</infon><infon key="name_4">surname:Williamson;given-names:MK</infon><infon key="name_5">surname:Antón-Plágaro;given-names:C</infon><infon key="pub-id_doi">10.1126/science.abd3072</infon><infon key="pub-id_pmid">33082294</infon><infon key="section_type">REF</infon><infon key="source">Science.</infon><infon key="type">ref</infon><infon key="volume">370</infon><infon key="year">2020</infon><offset>34101</offset><text>Neuropilin-1 is a host factor for SARS-CoV-2 infection</text></passage><passage><infon key="fpage">eabc5801</infon><infon key="name_0">surname:Brann;given-names:DH</infon><infon key="name_1">surname:Tsukahara;given-names:T</infon><infon key="name_2">surname:Weinreb;given-names:C</infon><infon key="name_3">surname:Lipovsek;given-names:M</infon><infon key="name_4">surname:Van den Berge;given-names:K</infon><infon key="name_5">surname:Gong;given-names:B</infon><infon key="pub-id_doi">10.1126/sciadv.abc5801</infon><infon key="pub-id_pmid">32937591</infon><infon key="section_type">REF</infon><infon key="source">Sci Adv.</infon><infon key="type">ref</infon><infon key="volume">6</infon><infon key="year">2020</infon><offset>34156</offset><text>Non-neuronal expression of SARS-CoV-2 entry genes in the olfactory system suggests mechanisms underlying COVID-19-associated anosmia</text></passage><passage><infon key="fpage">856</infon><infon key="lpage">60</infon><infon key="name_0">surname:Cantuti-Castelvetri;given-names:L</infon><infon key="name_1">surname:Ojha;given-names:R</infon><infon key="name_2">surname:Pedro;given-names:LD</infon><infon key="name_3">surname:Djannatian;given-names:M</infon><infon key="name_4">surname:Franz;given-names:J</infon><infon key="name_5">surname:Kuivanen;given-names:S</infon><infon key="pub-id_doi">10.1126/science.abd2985</infon><infon key="pub-id_pmid">33082293</infon><infon key="section_type">REF</infon><infon key="source">Science.</infon><infon key="type">ref</infon><infon key="volume">370</infon><infon key="year">2020</infon><offset>34289</offset><text>Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivity</text></passage><passage><infon key="fpage">437</infon><infon key="lpage">45</infon><infon key="name_0">surname:Oberdörster;given-names:G</infon><infon key="name_1">surname:Sharp;given-names:Z</infon><infon key="name_2">surname:Atudorei;given-names:V</infon><infon key="name_3">surname:Elder;given-names:A</infon><infon key="name_4">surname:Gelein;given-names:R</infon><infon key="name_5">surname:Kreyling;given-names:W</infon><infon key="pub-id_doi">10.1080/08958370490439597</infon><infon key="pub-id_pmid">15204759</infon><infon key="section_type">REF</infon><infon key="source">Inhal Toxicol.</infon><infon key="type">ref</infon><infon key="volume">16</infon><infon key="year">2004</infon><offset>34352</offset><text>Translocation of inhaled ultrafine particles to the brain</text></passage><passage><infon key="fpage">727</infon><infon key="lpage">733</infon><infon key="name_0">surname:Zhu;given-names:N</infon><infon key="name_1">surname:Zhang;given-names:D</infon><infon key="name_2">surname:Wang;given-names:W</infon><infon key="name_3">surname:Li;given-names:X</infon><infon key="name_4">surname:Yang;given-names:B</infon><infon key="name_5">surname:Song;given-names:J</infon><infon key="pub-id_doi">10.1056/NEJMoa2001017</infon><infon key="pub-id_pmid">31978945</infon><infon key="section_type">REF</infon><infon key="source">N Engl J Med.</infon><infon key="type">ref</infon><infon key="volume">382</infon><infon key="year">2020</infon><offset>34410</offset><text>A Novel Coronavirus from patients with pneumonia in China</text></passage></document></collection>
